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Abstract 
Epigenetic modifications, including DNA methylation and histone 
modifications switch the expression of genes on and off, and are crucial for 
normal development. Abnormal epigenetic events lead to carcinogenesis. 
Dietary factors have the ability to alter the epigenetic structure of genes and 
greatly contribute to the risk of colon cancer development.  Epidemiological 
studies have shown that compared to the US, East Asia has a much lower 
incidence of colon cancer.  One major difference in diet between these two 
populations is that East Asians consume more soy products.  Genistein, a 
soy-derived isoflavone has been shown to act as an epigenome modifier, 
and to have anti-cancer properties.   
We aimed to explore the role(s) of soy isoflavone genistein during the 
development of colon cancer.  Using a human colon cancer cell line DLD-1 
as an in vitro experimental platform, we have identified that genistein 
restored the expression of a Wnt antagonist sFRP2, which was silenced in 
colon cancer cells, by affecting the DNA methylation at the promoter of the 
gene. Consequently, the abnormally activated Wnt signaling was attenuated, 
leading to repressed cancer cell viability and increased apoptosis. By using 
an azoxymethane (AOM)-induced rat colon cancer model, we examined the 
ability of genistein to modify the epigenetic structure of Wnt signaling genes, 
which have been shown to be closely involved in colon carcinogenesis.  
Male Sprague-Dawley rats were fed a control (CTL), a soy protein isolate 
(SPI), or a genistein (GEN) diet from gestation through 13-wk of age.  The 
first sampling was conducted at 7 wk of age for pre-AOM analysis.  The 
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remaining rats were injected with AOM at 7-wk of age.  Descending colon 
was collected 6 wk later for evaluation of aberrant crypt foci (ACF), gene 
expression, and nuclear protein accumulation.  AOM injection induced 
aberrant nuclear accumulation of β-catenin in the CTL but not in the SPI or 
GEN groups.  Moreover, WNT target genes Cyclin D1 and c-Myc were 
repressed by SPI and GEN.  Meanwhile, SPI and GEN suppressed the 
expression of WNT signaling genes including Wnt5a, Sfrp1, Sfrp2, and 
Sfrp5 to the similar level to that of pre-AOM period.  Rats fed SPI and GEN 
had a decreased number of total aberrant crypts.  GEN feeding also 
resulted in a reduced number of ACF with N=3 per foci.  The reduction of 
WNT/β-catenin signaling was correlated with the decrease of total aberrant 
crypts.  By testing WNT/β-catenin signaling as a biomarker of colon 
carcinogenic potential, we showed the novel role of genistein as a 
suppressor of carcinogen-induced WNT/β-catenin signaling in preventing 
the development of early colon neoplasia. 
Next, we elucidated the epigenetic mechanisms by which genistein 
maintains a normal level of WNT genes during colon cancer development. 
We hypothesized that SPI and GEN induced epigenetic modifications on 
Sfrp2, Sfrp5, and Wnt5a genes, therefore suppressed their gene expression 
induced by AOM a level similar to that of the pre-AOM period.  We identified 
that in the post-AOM period the acetylation of histone H3 (H3Ac) was 
downregulated by SPI and GEN at the promoter region of Sfrp2, Sfrp5, and 
Wnt5a, which paralleled the reduced binding of RNA Polymerase II. Nuclear 
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level of histone deacetylase 3 (HDAC3) was enhanced by SPI and GEN.  
SPI and GEN suppressed the trimethylation of histone H3 Lysine 9 
(H3K9Me3) and the phosphorylation of histone H3 Serine 10 (H3S10P).  
Methylation of the specific region of Sfrp2, Sfrp5, and Wnt5a genes was 
increased by SPI and GEN, which was inversely correlated with reduced 
gene expression.  Bisulfite sequencing further confirmed that dietary 
genistein induced DNA methylation at CpG island of the promoter region of 
Sfrp5.  Importantly, this region includes a fragment that had decreased 
acetylation of histone H3.  Our study presents a potential epigenetic 
mechanism by which dietary genistein controls the responses of WNT 
genes during carcinogen induction, which involves DNA methylation, 
histone modifications, and their interactions at the regulatory region of 
genes.   
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Chapter 1: Introduction 
 Colorectal cancer (CRC) is the second deadliest carcinoma in the United 
States. Epigenetic modulations such as DNA methylation and histone 
modifications closely orchestrate the transcriptional activity of genes, and specific 
epigenetic structures are required for maintaining the normal function of living 
cells (1). Insufficient control of the epigenetic balance activates oncogenes and 
deactivates tumor suppressor genes, leading to the development of various 
cancers (2). Recently, colon cancer has been reported to occur through the 
accumulation of aberrant DNA methylation (3) and disruption of the histone codes 
(4). The Wnt signaling pathway plays a crucial role in normal colon epithelium 
development as well as in the tumorigenic steps (5; 6).  It is estimated that 
abnormal Wnt signaling is associated with approximate 90% of colorectal cancer 
cases (7). Increasing numbers of studies have reported that the Wnt signaling 
pathway is activated in colon cancer through epigenetic regulations (8). Soy 
isoflavone genistein, which is of great interest for its anti-cancer properties, has 
been recognized as an epigenetic regulator during cancer development (9). In 
vitro studies have demonstrated that genistein alters histone acetylation and 
DNA methylation, causing the silencing or activation of genes that are critical for 
cell cycle control and apoptosis in various cancers (4; 10; 11; 12).  Although it has 
been reported that a genistein-containing diet reduces the neoplastic lesions in 
colon, the underlying mechanism by which dietary genistein bestows its anti-
cancer property remains unclear. No in vivo study has been conducted to 
elucidate the mechanism of genistein-induced epigenetic modifications on colon 
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cancer development.  There is an urgent need to address how dietary genistein 
regulates WNT/β-catenin signaling activity at an epigenetic level, since this 
pathway is critical for maintaining colon health throughout life.  
 The objective of my study was to elucidate the mechanism of genistein-
mediated epigenetic modifications that maintain WNT/β-catenin signaling and 
repressing colon cancer development. We have identified that genistein, in 
addition to decreasing proliferation and promoting apoptosis of colon cancer 
cells, activates tumor suppressive Wnt genes through demethylation at their 
promoter regions (13; 14).  Moreover, we have recently identified that a lifelong 
exposure to dietary genistein prevented the carcinogen-induced overactivation of 
Wnt signaling, thereby reducing the frequency and severity of pre-neoplastic 
lesions in rat colons (15). Our studies have provided evidence that dietary 
exposure to genistein maintained Wnt signaling at a normal level in response to a 
carcinogen load by mediating the DNA methylation and/or histone modifications, 
and potentially affecting the interaction between these two on Wnt genes. This is 
the first study to identify the epigenetic effect of soy isoflavone genistein, which is 
critical for maintaining a normal level of Wnt signaling throughout life. Our study 
is beneficial for the advancement of the field related to the nutritional modulation 
on the epigenome.  
 Based on the knowledge we gained from the study, further research can 
be conducted to elucidate the effects genistein has on epigenetic modifiers, 
including the enzymes and binding factors involved in DNA methylation and 
histone modifications.  
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Chapter 2: Literature Review 
Colon cancer ranks fourth in the number of cause of death from cancer 
worldwide (16). It is a disease that develops over a relatively long period of time 
compared to acute type diseases (17). It takes up to about 20 years for normal 
colon epithelium to transform into adenoma, and it takes another 10 years to 
develop carcinoma.  
The development of colon cancer attributes to numerous factors. There 
are uncontrollable factors, such as one’s gender, ethnicity and family medical 
history. Colon cancer occurs more often in men than in women (COLORECTAL 
CANCER REPORT 2010 SUMMARY, 2011, IACR), and is less common in Africa 
and majority of Asia. The incidence and death rate increases with age. Only 20% 
of colon cancer cases are categorized as inherited type, while the other 80% are 
considered as sporadic cancers, which means that they developed naturally, 
probably caused by factors other than genetic susceptibility.  
Besides the above-mentioned factors that an individual cannot control, 
there are modifiable factors that we could adjust to lower the chance of 
developing colon cancer. Convincing evidence shows that increased tobacco use 
strongly correlates with an elevation of colon cancer (18). Besides, the type and 
amount of ingested food and beverage affect greatly on colon health (19; 20). As 
the end of gastrointestinal tract, the lumen side of colon directly exposes to and 
therefore is easily disturbed by pathogenic remnant or metabolites from the daily 
diet.  
	   4	  
It is much easier and less painful to revise and shift one’s lifestyle to 
include a healthy diet to prevent colon cancer than to treat the disease after its 
development. Therefore, elucidation of the colon cancer preventive potential of 
different diets and dietary compounds becomes ineligibly critical. To do so, we 
first must understand the molecular mechanisms that drive the initiation and 
progression of colon cancer. 
The term “Epigenetics” refers to heritable changes that alter gene 
expression and cell phenotype without changing the genetic sequence itself, and 
was coined by C.H. Waddington in 1942. Since then, tremendous work has been 
done to illustrate the fascinating role of the “layer above the genome” in 
controlling cellular gene expression in different life stages and environments. 
Epigenetic regulations, including DNA methylation, histone modifications, and 
micro-RNA (miR) regulation, closely orchestrate the transcriptional activity of 
gene by switching gene on and off without altering the DNA sequence. 
Furthermore, epigenome is required for keeping genetic activity stabilized and 
organized, and consequentially maintaining normal physiological functions.  
An aberrant epigenome structure activates genes that promote cancer 
development and progression, while suppressing tumor suppressor genes, 
leading to the development of various cancers (21).  Colon cancer occurs as a 
consequence of the accumulation of abnormal DNA methylation and the 
disruption of the histone codes (3). Dysregulated DNA methylation occurs at the 
earliest stages of colon cancer development in normal-appearing colon mucosa. 
Global DNA hypomethylation is a major characteristic of a cancer epigenome, 
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and causes chromosome instability and activates cancer-promoting genes (22; 23). 
However, increased methylation intensity at regulatory region of genes, such as 
promoter CpG-rich regions, which are normally unmethylated and facilitates 
transcription activation, results in the silencing of tumor suppressor genes (24). In 
addition to the DNA methylation status, the histone code is another regulator of 
gene expression. The majority of histone modifications occur at specific residues 
on the tails of histone H3 and H4, including acetylation, biotinylation, mono-, di-, 
tri-methylation, phosphorylation, ubiquitination, and sumoylation (25). In general, 
histone acetylation creates a loose, active chromatin structure, which allows the 
transcription machinery to bind to the DNA sequence, promoting gene 
expression. In contrast, histone methylation leads to a tight, repressive chromatin 
structure, which obstructs the initiation of transcription, suppressing gene 
expression. In addition to their individual impact on the genetic accessibility, DNA 
methylation and histone modifications crosstalk with each other, thereby 
determining the chromatin structure and transcriptional activity of gene.     
As one of environmental factors that modify cancer risk, dietary 
preferences and intakes and their association with cancer are constantly 
evaluated in epidemiologic investigations. Through numerous cohort studies, 
researchers have reached the consensus that a diet high in fat increases colon 
cancer risk, while a diet rich in fruits and vegetables help lower the risk of 
developing colon cancer.  Unlike genetic predeposition, one's diet is modifiable.  
Therefore, more and more efforts have been devoted to elucidate the impact of 
dietary factor on attenuating colon cancer development and progression. Food-
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derived natural compounds have been reported to prevent epigenetic 
dysregulation, and facilitate in reestablishing an organized epigenetic network. 
However, the other side of the coin is that cytotoxicity and other side effects were 
also observed in response to natural compounds. In order to take the most 
advantage of the anticancer properties of natural products, , it is necessary to 
understand the mechanisms of how these different bioactive dietary components 
affect epigenome in different conditions 
As was discussed in the above introduction, epigenetic instability greatly 
dysregulates gene expression network, and therefore has the ability to initiate 
and promote cancer development. Like genetic information, the epigenetic code 
is heritable. However, unlike the genomic sequence, epigenetic structure can be 
reshaped, which has the potential to offer access for the prevention and 
treatment of cancer by any compounds that target the epigenome. Therefore, for 
the past 15 years, the involvement of epigenetic in cancer has been intensively 
investigated. There are three major epigenetic regulations that attract cancer 
researchers the most are DNA methylation, histone modifications, and miR-
mediated regulations, and dietary component could interfere with all of these, 
thereby preventing or attenuating cancer development.  
During normal development, the colon epithelium is organized to maintain 
a homeostatic renewal status. Many signaling pathways are acquired to maintain 
this complexity, including the Wnt signaling pathway. The importance of Wnt in 
colon cancer development did not become clear until the discovery of mutated 
Adenomatous polyposis coli (APC) in many sporadic colon cancer cases 20 
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years ago (25). Suppression of APC was shown to lead to constitutive activation of 
Wnt signaling, which was later found to be a robust stimulator of cancerous 
growth in the colon (26). Wnt signaling is categorized as either canonical, which is 
Tcf/β-catenin dependent, or noncanonical, which is calcium related but Tcf/β-
catenin independent signaling (27). In general, the former one has been of more 
interest in the field of colon cancer research. Wnt signaling is initiated when a 
ligand protein, such as Wnt 1, binds to its frizzle receptor (FZ), and forms a 
complex with co-receptor LRP on the cell membrane. After associating and 
disassociating with several cytoplasmid components, including Dishevelled (Dvl), 
GSK3β, and Axin1, the signal is passed down to β-catenin, which then 
dissociates from APC, and translocates into the nucleus. After forming a complex 
with TCF/LEF in the nucleus, β-catenin then stimulates the expression of Wnt 
target genes, including those that are critical for cell cycle control, such as Cyclin 
D1 and c-Myc (28). Wnt signaling also interplays with other cellular signaling 
pathways, thereby supervising cancer cell growth (FGF and BMP) (29), migration 
(MMPs) (30), viability (Bcl9) (31), and adhesion (CD44 and LGR5) (32) as well. As 
colon develops during normal physiological conditions, Wnt signaling is 
supervised and maintained at a normal active level by its antagonists, such as 
secreted frizzled-related protein sFRP1, sFRP2, and sFRP5 (33). By restraining 
Wnt proteins, such as WNT1, in the cytoplasma, Sfrps obstruct the initial binding 
of Wnt ligand protein to FZ, thus preventing the signal transduction to the nucleus. 
Another Wnt antagonist, Dikkopf-1 (DKK-1), is a secretary protein that 
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competitively binds to LRP with Wnt ligand and prevents downstream signaling 
(34).   
Silencing of Wnt antagonist leads to uncontrolled Wnt signaling, which is 
closely associated with pathogenesis, thus promoting colon carcinogenesis (35), 
and this process is likely strongly regulated by epigenetic events.  Abnormal Wnt 
signaling was observed in approximately 90% ofcolorectal cancer cases (36), and 
an increasing body of evidence has shown that silencing of Wnt antagonists 
results from epigenetic dysregulation. Hypermethylation at the promoter region of 
Sfrp1, Sfrp2, Sfrp4, Sfrp5 and Wif were reported in various colon cancer cell lines 
and it occurs from the earliest stages through the whole span of colon caner 
development. After treating colon cancer cells with a demethylating agent, such 
5-aza-cytidineas and 5-aza-2'-deoxycytidine, the gene expression of Sfrps and 
Wif was restored, resulting in attenuation of constitutively activated Wnt signaling 
(37; 38; 39). Treating with a histone deacetylase (HDAC) inhibitor, which promotes 
histone acetylation, restored the expression of sFRP1 and sFRP2 in gastric 
cancer cell (40). To date, however, there is little evidence shwoing the impact of 
histone modifications on re-establishing sFRPs expression in colon cancers. 
Another Wnt inhibitor, DKK-1 was not as effective as Sfrps in attenuating 
aberrant Wnt signaling, but the re-expression of this gene suppressed colon 
cancer growth (41; 42). Decreased DNA methylation was shown to upregulate the 
expression of DKKs (43), and methylation at promoter CpG island of DKK-1 was 
identified in multiple colon cancer cell lines and it is proposed that epigenetic 
silencing of DKK-1 happens more often in higher stage colon carcinomas. Beside 
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DNA methylation, histone modification also plays a role in regulating DKK-1 
expression. It has been reported that DKK-1 expression was restored by histone 
acetylation at histone H3, and this was associated with decreased cell 
proliferation in colon cancer cell line SW480 and HCT15 (44). In addition to the 
regulation that occurs at the initial steps of Wnt signaling, the pathway is also 
mediated at other levels as well. DACT3, which interferes with Dvl during 
signal transduction and thereby antagonizes Wnt signaling, has been 
reported to be repressive in colorectal cancer through histone alteration 
but not promoter methylation. Using combination inhibitor of histone 
methylation and acetylation, the depression on DACT3 expression was 
depleted (45). 
Emerging studies have shown that Wnt signaling is also regulated through 
miR-mediated mechanism in colon cancer.  MiR-34, a downstream target of p53, 
was reported to be a Wnt suppressor by interacting with the UTR of WNT1, LRP6 
and β-catenin gene (46). Tumor suppressive miR-101 showed a gradient decrease 
from normal mucosa, to the cancerous epithelium, and to the invasive front of 
cancerous tissue (47). Silencing of miR-101 increased Wnt signaling by 
upregulating β-catenin nuclear accumulation. On the contrary, overexpression of 
miR-101 resulted in a decrease of β-catenin in the nucleus. miR-1290 was 
increasingly expressed in colon cancer tissue, and has been proposed to 
promote tumor development (48). Stabilized expression of miR-1290 promoted 
colon cancer cell SW620 reprogramming by silencing DKK-3, upregulating Wnt 
signaling, and thereby activating c-Myc. Overall, appropriate Wnt signaling has 
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been shown to be critical for maintaining colonic homeostasis, making it critical to 
unravel the epigenetic modifications that occur when this pathway is 
dysregulated during colon cancer development.  
 Genistein, a major isoflavone derived from soybeans, has been reported 
to be an epigenome modifier, and exerts anti-cancer effects (9). Recently, Zhang 
et.al. reported that feeding genistein-containing diets decreased the formation 
and severity of aberrant crypt foci, which were pre-neoplastic lesions after 
carcinogen-induction in rat descending colons (15). Wnt signaling was protected 
from carcinogen-induced over-activation by the genistein diets. In vitro studies 
suggest that after genistein treatment, colon cancer cells showed increased 
apoptotic activity and decreased cell proliferation. Genistein treatment restored 
the expression of Wnt5a and sFRP2 by acting as a DNMT inhibitor and 
promoting promoter demethylation, thereby attenuating aberrant Wnt signaling in 
colon cancer cells (39; 49). Genistein has also been reported as a histone modifier. 
It induced the expression of DKK-1 through upregulating histone H3 acetylation 
at gene promoter (44). Although genistein had been reported to regulate miRs in 
several types of cancers (50), little is known about miR action in colon cancer. 
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Chapter 3: Review of Genistein, An Epigenome Modifier During Cancer 
Prevention 
Introduction 
Dietary components have long been investigated for their involvement in 
carcinogenesis, and among them are soy products, which have been highlighted 
for their cancer-inhibiting activity (51; 52).  The connection between the intake of 
soy foods and incidence of cancer has been made from epidemiological studies 
(53; 54; 55; 56).  For instance, the higher intake of a soy-rich diet is associated with a 
lower incidence of colorectal cancer in Asian countries (53; 54; 57).  It has also been 
shown that dietary soy intake contributes to reduced prostate cancer incidence 
(58; 59).  There is an increasing body of evidence suggesting that genistein, a soy-
derived isoflavone, is responsible for this anticancer property of soy (60; 61; 62).  A 
recent in vivo study indicated that prepubertal genistein exposure suppressed 
chemical-induced mammary tumors (63). Dietary genistein has also been reported 
to reduce chemical-induced prostate cancer (64) and colon cancer (65; 66) in rats.  
In vitro studies conducted in different cancer cell lines confirmed that by affecting 
various cellular targets, including several critical tumor suppressor genes, 
genistein treatment repressed cancer cell proliferation (14; 67; 68), induced 
apoptosis (13; 14; 69), and led to cell cycle arrest (70; 71; 72).  However, the mechanism 
behind genistein’s ability to modulate the expression of tumor-promoting and -
suppressing genes during cancer development remains unclear.   
The interactions between diet and cancer at the epigenetic level have 
most recently been investigated at the level of histone modification and DNA 
methylation (73; 74). Importantly, early environmental influences, such as dietary 
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food intake and manipulation of maternal nutrition during gestation, might disrupt 
normal development, inducing alterations of postnatal growth and physiological 
outcomes in later adult life of the offspring, leading to elevated risks of certain 
chronic diseases, including cancers (75).  Evidence from animal models suggests 
that genistein can be transferred from dams to pups via the placenta and during 
breast feeding (76; 77).  Therefore, it is critical to elucidate the mechanism of 
genistein-programmed epigenetic modifications during cancer development.  
Genistein has been shown to play important roles in cancer epigenetics (78; 79).  In 
this review, we discuss and describe the protective role of genistein in cancer 
development as well as its role in future therapeutic applications with an 
emphasis on epigenetic mechanisms.   
Genistein alters the configuration of chromatin 
Histone modification is one of the well-defined epigenetic events, and is 
critical for modulating transcriptional activity (25).  The activation of gene 
transcription requires certain chromatin configurations, which, for example, can 
be obtained by acetylation or methylation at specific sites of histone tails. 
Histone acetylation is responsible for a loosen chromatin structure, which 
leads to the recruitment of transcription activation machinery (21).  By conducting 
the chromatin immunoprecipitation assay, a method for detecting histone 
modifications, it has been shown that genistein alters the pattern of histone 
acetylation and induces tumor suppressor gene expression (80; 81).  Genistein 
increased the acetylation of histone H3 and H4, especially H3 lysine 4 around the 
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transcription start sites of p21 and p16, and upregulated the expression of these 
two well-known cell cycle-related tumor suppressors in prostate cancer cells (80).  
In the same study, after genistein treatment, the increase of p21 and p16 was 
accompanied by a decrease of cyclins, and an induction of cell cycle arrest.  
Similarly, the activation by genistein of PTEN, CYLD, p53 and FOXO3a involved 
the acetylation of histone H3 lysine 9, one of the heterochromatic domains at the 
promoter region of prostate cancer cells.  The increased expression of above 
tumor suppressor genes has been shown to attenuate the phosphorylation of 
AKT and the binding activity of NF-kappa B, therefore leading to inhibition of the 
AKT signaling pathway, which is related to cancer cell survival (81).  In addition to 
histone acetylation, methylation at certain residues of histone tails defines the 
transcriptional activity of genes.  For example, methylation of histone H3 lysine 9 
causes silencing of gene transcription, while on the contrary, methylation of 
histone H3 lysine 4 leads to activation of gene transcription (82).  Genistein has 
been shown to decrease methylation of H3 lysine 9, a configuration of the 
chromatin associated with suppression of transcription, at the promoter region of 
PTEN and CYLD, thus restoring the expression of these two genes in prostate 
cancer cells and suppressing AKT signaling (81).  Additionally, B-Cell translocation 
gene 3 (BTG3), another tumor suppressor candidate, has been shown to be 
silenced by hypermethylation in prostate cancer.  In this case, genistein, 
increased the dimethylation of H3 lysine 4 and induced BTG3 upregulation (12). 
While studies have demonstrated that genistein affects chromatin 
configuration, leading to an activation of tumor suppressor genes and affecting 
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cancer cell survival, the mechanism of how genistein induces gene- and residue- 
specific histone modification remains unclear.  Furthermore, the importance of 
other histone modifications, such as phosphorylation and ubiquitination, has not 
been thoroughly addressed following genistein treatment.   
Genistein modulates DNA methylation 
DNA methylation is another major epigenetic modification that has been shown 
to be strongly correlated to cancer development (83; 84).  Global hypomethylation 
has been observed and is related to the vast overexpression of oncogenes which 
are normally inactive in healthy tissues (85).  Hypermethylation of CG-rich regions, 
so-called CpG islands, at the regulatory region of tumor suppressor genes, which 
subsequently causes gene silencing, has been detected in various cancers.  The 
DNA methylation profile has been often used as a therapeutic biomarker during 
cancer therapy due to its ability to reflect abnormality at very early stage of 
cancer development, to categorize tumor type, and more importantly, to predict 
and characterize the efficacy of anticancer agents (84).  Notably, dietary 
component have been shown to affect DNA methylation patterns.  Specifically, 
genistein has been reported to modulate DNA methylation in in vitro studies (10; 12; 
39; 49; 86).   
Our group has been studying the effect of dietary genistein on colon 
cancer development with a focus on WNT signaling, the abnormality of which 
leads to colon carcinogenesis (13; 39).  In particular, we investigated the mode of 
action of genistein by understanding the underlying epigenetic mechanisms 
involved in the regulation of WNT signaling.  WNT signaling is not only critical for 
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normal cell proliferation and differentiation, but is also closely involved in 
carcinogenesis.  Notably, abnormally activated WNT signaling has been detected 
in the majority of colon cancer cases (35; 87; 88).  Hypermethylation-silenced WNT 
antagonists have been often observed in colon tumors as well as in colon cancer 
cell lines, and the silencing of WNT antagonist genes causes the disruption in the 
control of WNT signaling (89; 90; 91).  Using methylation-specific PCR and bisulfite 
genomic sequencing, we identified that genistein reactivates WNT5a, one of the 
WNT signaling antagonists, by demethylating the promoter region in colon 
cancer cell line SW1116.  Additionally, we observed a concomitant inhibition of 
cell growth following genistein treatment (13).  Zhang et al. has reported that 
genistein restores the expression of another WNT antagonist, sFRP2, by 
mimicking the effect of DNMT inhibitor 5-Aza-C in colon cancer cell line DLD-1.  
Following genistein treatment, the reduction of DNA methylation was detected at 
two CpG islands around the sFRP2 promoter region.  Additionally, the decrease 
of cell proliferation and increase of apoptosis were detected following genistein 
treatment (39).  Our studies provided the direct evidence indicating that genistein 
can reduce DNA methylation at promoter regions of WNT genes, thereby 
inducing their expression in colon cancer cells. 
To further elucidate the potential mechanism behind genistein’s ability to 
influence DNA methylation patterns, several factors have been introduced and 
highlighted for their importance in altering DNA methylation, and among them are 
DNA methyltransferases (DNMTs) (83).  It has been suggested that genistein acts 
as a DNMT inhibitor, thereby causing the demethylation of the CpG islands in the 
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promoter of genes, leading to the reactivation of those hypermethylation-silenced 
tumor suppressor genes, such as p16, retinoic acid receptor beta (RARbeta), 
and O6-methylguanine methyltransferase (MGMT) in esophageal squamous cell 
carcinoma and prostate cancer cells (10; 11; 12).   
In vivo studies have provided evidence suggesting that dietary genistein 
exposure mediates the DNA methylation profile of genes.  Using the mouse 
differential methylation hybridization array, gene-specific alteration of DNA 
methylation was observed in mice fed a genistein-rich diet compared to those fed 
a control casein diet (92).  Moreover, maternal exposure to dietary genistein 
altered the epigenome of offspring in viable yellow agouti (Avy/a) mice.  The 
agouti gene in the mouse with Avy genotype includes an intracisternal A particle 
(IAP) retrotransposon inserted in its promoter.  The IAP is a potent cis-activating 
factor and when unmethylated, overwrites the transcriptional control from the 
endogenous promoter and induces overexpression of the Agouti gene, causing 
phenotypes of yellow-coat and obesity.  Maternal genistein induced an increase 
of CpG methylation in the Avy IAP region in offspring rats and this persisted into 
adulthood.  Therefore, maternal genistein decreased the expression level of the 
Agouti gene and protected offspring rats from being obese (93).  This study raised 
the interest in investigating the epigenetically-programmed response of animals 
to their early life, in particular, to the maternal exposure to genistein.  Using a 
chemical-induced experimental colon carcinogenesis model in rats, we were able 
to directly study and evaluate the effect of dietary exposure to genistein on colon 
cancer development.  Our preliminary results have shown that lifelong exposure, 
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which includes the maternal period, to genistein prevents chemical carcinogen-
induced activation of WNT signaling, and reduces colon preneoplastic lesions, 
indicating that the early exposure to genistein, before the animals encounter a 
carcinogen, assists in reducing colon abnormality in their later lives.  Our 
observations suggest that genistein programmed the response of the important 
cancer-related signaling pathway, and therefore protected animals from cancer 
initiation.  However, while the epigenetically-regulated mechanism of tumor 
suppressor gene activation by genistein has been shown in cancer cells, it has 
not been clearly addressed in animal model. 
As critical regulators of the epigenome, histone modifications and DNA 
methylation communicate with each other, providing the correct configuration for 
assisting or preventing transcription machinery initiation, which activates or 
represses gene expression during normal developmental events as well as in 
carcinogenesis.  Histone methylation can direct DNA methylation, and DNA 
methylation has the ability to affect some histone modifications, and this two-way 
crosstalk has been shown to be highly associated with the interplay between 
histone and DNA methyltransferases (94).  Methylation of histone H3 lysine 4 
residue has been shown to prevent DNMTs from binding to CpG sites, therefore 
attenuating DNA methylation at specific regions of genes (95).  Moreover, DNMTs 
and methyl-binding domain proteins (MBDs) can recruit histone deacetylases, 
leading to histone deacetylation and causing transcription repression (96).  It has 
been shown that genistein increases the methylation of histone H3 lysine 4, while 
decreasing the activity of DNMT and MBD2 (97), indicating the complexity of 
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genistein-induced epigenetic modifications in cancer cells.  Although there is an 
increasing body of evidence demonstrating that genistein alters the pattern of 
histone modifications and DNA methylation in various cancer types, there are no 
known studies indicating whether these two genistein-induced epigenetic 
alterations are independent or dependent of each other.  More studies have to be 
conducted to investigate the mechanisms behind genistein’s ability to direct the 
potential interaction between histone modifications and DNA methylation, and to 
determine which of these functions as the primary target of genistein.  
Importantly, the more knowledge we gain from these future studies, the better we 
understand and are able to define efficient and accurate epigenetic markers for 
genistein treatment of cancer development.  
Conclusions 
Cancer development is a continuously progressive event, involving the 
activation of oncogenes and the loss of tumor suppressor genes by alterations of 
the epigenome.  Epigenetic modifications, such as histone modifications and 
DNA methylation, are dynamic, reversible and dietary factor-responsive events.  
Overwhelming evidence has shown that dietary components influence the 
programming of the epigenome as well as the risk of developing cancer.  
Therefore, in recent studies that investigated the relationship between diet and 
cancer development, the effects of dietary components, such as genistein, on 
cancer development are often addressed through understanding their roles in 
epigenetic modifications.  Many types of studies have shown that genistein 
restores and upregulates tumor suppressor genes by modifying histone 
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configurations at specific residues and or altering DNA methylation patterns at 
promoter CpG islands.  Despite the fact that evidence from in vitro studies 
indicates the promising role of genistein in affecting cancer cells, more research 
needs to be conducted to reveal the underlying mechanisms behind genistein’s 
ability to induce gene-specific alterations and trigger site-specific modifications.  
Additionally, the interaction between histone modifications and DNA methylation 
should also be addressed in future studies using genistein-treated cancer cells.  
Dietary genistein has been shown to affect DNA methylation patterns at specific 
genes in mice.  Early dietary exposure, especially maternal exposure, has been 
of great interest for its potential protective effect against cancer development in 
later life, and our animal study provides the evidence and mechanism of 
genistein-programmed colon cancer prevention.  All of the studies point out the 
necessity for in vivo models to be studied to investigate the potential of dietary 
genistein to prevent cancer through epigenetic programming.  Moreover, the 
identification of cancer- and gene-specific epigenetic markers will provide insight 
into genistein’s involvement in carcinogenesis and will allow for designing future 
therapeutic strategies for cancer prevention and treatment.   
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Chapter 4: Genistein Attenuates WNT Signaling By Up-regulating sFRP2 In 
A Human Colon Cancer Cell Line 
Introduction 
The uncontrolled cell growth that causes cancer results from aberrant cell 
signaling due to a combination of genetics and environmental exposures, 
including the foods we eat.  This report analyzes the interactions between WNT 
signaling, the WNT antagonist sFRP2, and soy genistein in colorectal cancer line 
DLD-1.   
Genistein, one of the dietary isoflavones from soy, has been reported to 
have an anticancer effect (62; 79). While colorectal cancer (CRC) is one of the most 
prevalent neoplasms across the world (57; 98), epidemiological studies have shown 
that the higher dietary intake of soy products contributes to the lower incidence of 
CRC in Asian countries (53; 54; 57). In vitro data showed that genistein inhibits the 
growth of colon cancer cells, including the human colon cancer cell line DLD-1 
(66; 99).. A recent study showed that soy isoflavones composed of genistein, 
daidzein and glycitein triggered apoptosis in DLD-1 cell through estrogen 
receptor β (100).  Genistein also affects the antioxidant pathway and protects cells 
from oxidant stresses (101). Genistein has been shown to induce epigenetic 
changes in several cancer cell lines (10; 12; 80; 81) and in the in vivo animal models 
(93; 102). Furthermore, these and other studies suggest that genistein, as a dietary 
component, may affect DNA methylation.   
WNT family members are highly conserved, secreted signaling molecules 
that play important roles in both tumorigenesis and normal development and 
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differentiation (7; 103; 104). The WNT/β-catenin pathway is highly involved in colon 
carcinogenesis (35; 87; 88).  Largely WNT signaling starts with the binding of a WNT 
protein, such as WNT1, to its membrane receptor (105).  Through several 
cytoplasmic relay components, the WNT signal is delivered to β-catenin, which 
then translocates into the nucleus, where it forms a complex with TCF and 
activates transcription of WNT target genes. In the cytosol, phosphorylation by 
GSK3β/Axin complex, leads to catalysis of β-catenin (28; 106).  Aberrant WNT 
signaling occurs in almost all CRC cases (5). Malfunctioning WNT signaling that 
results in high levels of nuclear β-catenin leads to subsequent transcriptional 
activation of downstream genes which may be responsible for colon 
tumorigenesis (107).  Our previous study showed that genistein regulates the WNT 
signaling pathway in colon cancer cells through demethylation of WNT genes (49). 
The secreted, frizzled-related proteins, including sFRP2, sFRP1, sFRP4 
and sFRP5, comprise a group of WNT antagonists. As currently understood, 
WNT proteins bind to frizzled receptors and LRP5/6 co-receptors on the cell 
surface. sFRPs function as antagonists to WNT proteins through competitive 
binding to frizzled receptors (89; 108). Due to their putative WNT-inhibitory activity, 
sFRPs have been postulated to serve as tumor suppressors.  The expression of 
sFRPs has been shown to be affected by epigenetic silencing (91; 109).  
DNA methylation at CpG islands is a major epigenetic modification that 
strongly correlates to carcinogenesis (83; 84), with findings that  a series of genes 
become hyper- or hypo-methylated during tumorigenesis (110). Both in CRC 
tissues and certain colon cancer cell lines, promoter hypermethylation of sFRPs 
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genes was detected , which leads to reduced sFRP levels and thereby induces 
aberrant WNT signaling (89; 90; 111). Furthermore, DNA methylation can be affected 
by bioactive food components. For example, genistein has been reported to 
modulate DNA methylation in both in vitro and in vivo studies (4; 10; 12; 93; 110; 112).  
In this study, we have analyzed the possible impact of genistein on 
epigenetic regulation of sFRP2 in colon cancer cells. Here we show, for the first 
time, that in human cancer cell line DLD-1 genistein can attenuate the WNT/β-
catenin signaling pathway through restoring sFRP2 expression by demethylation 
of CpG islands in the sFRP2 promoter region. We conclude that genistein 
constricts colon cancer cell growth by assuaging aberrantly functioning WNT 
signaling.  
Materials and Methods 
Cell culture and treatments 
The human colon cancer cell line DLD-1 (purchased from ATCC, Manassas, VA) 
was maintained in minimum essential medium (MEM, SCS Cell Media Facility at 
the University of Illinois, Urbana, IL), supplemented with 10% (v/v) fetal bovine 
serum (FBS, Mediatech, Herndon, VA) in 5% CO2: 95% air at 37°C. Genistein 
(aglycone equivalent, provided by Dr. William G. Helferich, University of Illinois) 
was dissolved at a stock concentration of 75 mmol/L in DMSO. DLD-1 was plated 
at 0.2 million per 60 mm culture dish in regular MEM containing 10% (v/v) FBS 
and 1% antibiotic-antimycotic solution (ABAM, Mediatech). After 14 h incubation, 
cells were subjected to a 4-d treatment, either with MEM containing 0.1% DMSO 
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(v/v) as control, or 75 µmol/L genistein. The 75 µmol/L genistein treatment was 
based on preliminary study using 1, 5, 25 and 75 µmol/L with exposure times of 
1, 2, 3, and 4 d in DLD-1 cells.  The combination of 75 µmol/L of genistein with 4-
d treatment gave the most inhibition of cell proliferation (data not shown).  In fact, 
4-d treatment with 75 µmol/L of genistein was tested in our previous study and 
showed the maximal effect on one of the WNT signals (13).  Therefore, in this 
study we chose 75 µmol/L of genistein for 4 d as the treatment. Treatment media 
were refreshed every 2 d. Each treatment group had three replicates.  
For methylation selective PCR (MSP) sample preparation, 0.2 million cells were 
plated per 60 mm culture dish in regular MEM containing 10% (v/v) FBS and 1% 
ABAM. After 14 h incubation, cells were subjected to either a 2-d 5-aza-cytidine 
treatment, with MEM (Control) or MEM containing 1 µmol/L 5-aza-cytidine, or a 
4-d genistein treatment as described above. Treatment media were refreshed 
every day for 5-aza-cytidine and every other day for genistein. Each treatment 
group had three replicates. 
For preparing samples for immunoblotting, ten million cells were plated per 150 
mm culture dish in regular MEM containing 10% (v/v) FBS and 1% ABAM. After 
14 h incubation, cells were subjected to a 4-d treatment either with MEM contains 
0.1% DMSO (v/v) (Control), or 75 µmol/L genistein. Treatment media were 
refreshed every 2 d. Each treatment group had three replicates.  
Quantitative real-time PCR 
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After treatments, cells were harvested with TRI Reagent (Sigma-Aldrich) for total 
RNA isolation following the manual provided by the manufacturer. RNA 
concentrations were detected by spectrophotometer (BioRad SmartSpec Plus). 
cDNA was synthesized from RNA using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA) in a Thermal Cycler 2720 
(Applied Biosystems). In each reaction system, 2 µg of total RNA were used in a 
20 µL volume containing 1× RT buffer, 4 mmol/L dNTPs, 1× RT random primers, 
and 2.5 U/µL MultiScribe Reverse Transcriptase (Applied Biosystems). cDNA 
synthesis was performed following this program: 25°C for 10 min, 37°C for 120 
min, and 85°C for 5 sec. cDNA was then analyzed by two-step real-time PCR 
using a 7300 real-time PCR system (Applied Biosystems) and detected with 
SYBR Green. In each reaction, 25 ng of synthesized cDNA were used in a 20 µL 
volume containing 10 µL SYBR Green master mix (2x, Applied Biosystems) and 
0.25 µmol/L of each primer. RT-PCR was performed using the following program:  
95°C for 10 min, followed by 35 cycles of 95°C for 15 sec and 60°C for 1 min. 
After PCR, melting curves were acquired stepwise from 55 to 95°C to ensure that 
a single product was amplified in the reaction. A dilution series was used to 
establish a standard curve, with a slope of -3.3 ± 0.1, R2 of 0.99 ± 0.01. 
Ribosomal protein L7a was a validated internal control which our lab had been 
continuously using in genistein treatment. The mRNA levels of the target genes 
were expressed as the ratio of the target gene to L7a mRNA. The primers used 
in this study are listed in Table 1.  
Methylation selective PCR (MSP) 
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Cells were plated and treated as mentioned before. On d 4, cells were scraped 
using 1x PBS and collected by centrifuging. Genomic DNA was isolated with 
DNeasy Tissue Kit (Qiagen, MD). DNA concentration was determined by 260 nm 
absorbance. For each sample, 2 µg of total genomic DNA was treated with 
sodium bisulfite using the EZ Methylation-Gold kit (Zymo Research). Ten ng of 
final product was then used in each MSP reaction in a 20 µL volume containing 
10 µL SYBR Green master mix (2x, Quanta) and 0.25 µmol/L of each primer. For 
sFRP2, two pairs of methylated (M) primers (MSP sFRP2 M1 and MSP sFRP2 
M2) were designed to analyze the two CpG islands at the 5ʹ′ proximal region 
predicted by CpGPlot (www.ebi.ac.uk/emboss/cpgplot/). Control of the bisulfite 
reaction was done using one pair of unmethylated (U) primers (MSP L7a U) 
amplifying the coding region of L7a. Unless otherwise mentioned, all positions 
were numbered according to the transcription start site +1. Generally, the “C” of a 
methylated “CpG” will remain “C” after bisulfite conversion, and the “C” of an 
unmethylated “CpG” will be converted to “U” and changed to “T” after the PCR 
process. PCR was performed in a Thermal Cycler 2720 using the following 
program:  95°C for 10 min; followed by 35 cycles of 95°C for 30 sec,  primer Tm 
for 30 sec and 72°C for 1 min; 72°C for 7 min. Samples from at least three 
independent experiments were analyzed and presented.  The primers used in 
this analysis are listed in Table 1. 
Protein isolation and immunoblotting 
Cells were lysed in sample diluting buffer (0.125 mol/L Tris–HCl, pH 6.8, 1% 
SDS, 0.04% bromophenol blue, and 20% glycerol, v/v). Total protein 
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concentrations were determined by Lowry protein assay. For extracting protein 
from different cellular compartments, cells were washed and dislodged twice with 
ice-cold PBS and collected by centrifugation at 500 × g. Cell pellets were lysed 
with fresh lysis buffer (20 mmol/L HEPES pH 7.9, 10 mmol/L sodium chloride, 1.5 
mmol/L magnesium chloride, 0.2 mmol/L EDTA, 20% glycerol v/v, 1 mmol/L DTT 
(Roche, USA), 1 mmol/L PMSF (Sigma, USA), 1× protease inhibitor cocktail 
(Roche, USA), and 0.1% Igepal CA-630 v/v) on ice for 15 min and centrifuged 
again. Lysis was repeated in the resuspended pellet, followed again by 
centrifugation at 500 × g. The precipitates were then incubated with fresh nuclear 
extraction buffer (20 mmol/L HEPES pH 7.9, 400 mmol/L sodium chloride, 1.5 
mmol/L magnesium chloride, 0.2 mmol/L EDTA, 25% glycerol v/v, 1 mmol/L DTT, 
1 mmol/L PMSF, 1× protease inhibitor cocktail) at 4°C for approximately 30 min. 
Nuclear protein extracts were then collected from the supernatants after 
centrifugation at 12,000 × g. Protein concentration was determined by Lowry 
assay.  
For Western blot analysis, total or nuclear protein was size-fractionated on a 12% 
Tris–HCl polyacrylamide gel and transferred at 14 V onto a PVDF membrane 
(Bio-Rad, Hercules, CA) at 4°C. Immunoblotting with primary and secondary 
antibodies was done according to the manufacturers’ instructions. Briefly, PVDF 
membranes were incubated with blocking solution containing 1% (w/v) nonfat dry 
milk, 20 mmol/L Tris–HCl, pH 7.6, 137 mmol/L NaCl, and 0.1% (v/v) Tween-20 
(TBS/Tween) for 1 h at room temperature. Primary antibodies were diluted in 1% 
nonfat dry milk (Carnation) blocking solution according to manufacturers’ 
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instructions and incubated at 4°C overnight. Subsequently, the membranes were 
washed with blocking solution containing 1% (w/v) nonfat milk 5 times for 5 min 
each time. Goat anti-rabbit HRP-conjugated secondary antibody was diluted 
1:10000 in blocking solution containing 1% (w/v) nonfat dry milk and incubated 
for 1.5 h at room temperature. After 5x 5 min washing in blocking solution 
containing 1% (w/v) nonfat dry milk and 2x 5 min in TBS/Tween, the membranes 
were exposed to the enhanced chemiluminescence reagent SuperSignal West 
Dura (Pierce). Signals were detected and quantified using ChemiDoc XRS 
imaging system (Bio-Rad). Antibodies used in the present study were purchased 
from the following companies: Cell Signaling: Phospho-β-catenin 
(Ser33/37/Thr41), and β-catenin; Santa Cruz:  Lamin A (H-102), and Actin (I-19). 
Trypan blue cell viability assay 
The trypan blue dye exclusion test was used to determine cell viability. Viable 
cells with intact cell membranes exclude the dye while dead cells take up the 
coloring agent. Cells were trypsinized after genistein treatment as described 
above, stained with 1% Trypan blue (Mediatech Inc., Herdon, VA), and cell 
numbers were counted using a hemocytometer. Both the numbers of stained 
cells and the total numbers of cells were counted. The percentage of viability is 
calculated as the percentage of unstained cells in the whole cell population in 
control.  
WST-1 cell proliferation assay 
For cell proliferation measurement, a total of 3,000 cells in 100 µL medium were 
plated into individual wells of a 96-well cell culture plate (Corning Inc, Corning, 
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NY) according to the manufacturer’s instruction (Roche Applied Science, 
Indianapolis, IN), and then subjected to the treatments as described above. 
Reagent WST-1 was added to the wells at the end of treatment, and incubated 
for 2.5 h at 37°C. The absorption of WST-1 was measured at 450 nm 
(measurement wavelength) and 630 nm (reference wavelength) using an 
absorbance microplate reader ELx800 (BioTek, Winooski, VT).  
Cell apoptosis assay 
Apoptosis of DLD-1 cells were analyzed by flow cytometry using Annexin V-FITC 
Apoptosis Detection Kit (BioVision Research Products, Mountain view, CA). 
Briefly, after 4-d treatment with genistein, cells were incubated with Annexin V-
FITC and Propidium Iodide (PI) and subjected to flow cytometry analysis. Data 
from flow cytometry was analyzed by software FCS 3.0. 
Statistical analysis 
All data in current study are presented as the means ± SEM of replicates from 
independent experiments and analyzed by one-way ANOVA with repeated 
measures followed by Fisher’s t test (SAS Institute Inc., Cary, NC). Data were 
considered to be statistically significant at p <0.05.  
A box plot was used to analyze the data from the WST-1 cell proliferation assay. 
The lower line in the box represents Q1, the top point of the lower quartile; the 
middle line in the box represents Q2, the median point; and the upper line in the 
box represents Q3, the lowest point of the upper quartile. The smallest value is 
calculated as Q1 − 1.5 × (Q3 – Q1) and is represented as the end point of the 
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lower whisker; the largest value is calculated as Q3 + 1.5 × (Q3 – Q1) and is 
represented as the end point of the upper whisker.  
Results 
Effects of genistein treatment on DLD-1 cell viability and cell proliferation 
The effects of genistein on cell viability and cell proliferation were 
assessed at the end of the 4-d treatment. In the presence of genistein, a 
significant inhibition of cell viability was observed (Figure 4.1A). The number of 
viable cells in the genistein-treated cells decreased by 80% compared to the 
control cells. To determine whether genistein affects DLD-1 cell proliferation, a 
WST-1 assay was performed. The absorbance reading for WST-1 was 4-fold 
lower in the genistein-treated group (Figure 4.1B). This lower level of 
absorbance implies a significant decrease in cell proliferation in the genistein-
treated cells (p <0.01).   
Genistein treatment increases apoptosis in DLD-1 cells  
To determine whether the inhibition of DLD-1 cell proliferation by genistein 
was caused by the induction of apoptosis, the cells were dual-stained with 
Annexin-V-FITC and Propidium Iodide after the 4-d treatment and then analyzed 
by flow cytometry. The number of apoptotic cells (lower right quadrant) was 
higher in the genistein-treated group (11.97% of the whole cell population) than 
in the Control group (2.67%; Figure 2.2A).  The rate of apoptosis was increased 
by about three-fold (Figure 2.2B). The result indicates that genistein affects 
DLD-1 cell growth by inducing apoptosis.  
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WNT signaling is attenuated after genistein treatment 
WNT signaling plays a key role in various events related to cell 
metabolism (113; 114) and is often affected in cancer cells, as seen by higher levels 
of β-catenin in the nucleus of most tumor cells (115).  To determine whether the 
genistein-induced changes in DLD-1 cell viability, proliferation, and apoptosis are 
resulted from genistein’s effect on the aberrant WNT signaling in the tumor cell 
line, nuclear β-catenin protein level was examined. In the genistein-treated cells, 
the nuclear β-catenin protein is decreased by almost 50% (Figure 4.3A). This 
significant reduction of nuclear β-catenin accumulation suggests that genistein 
attenuates aberrant WNT signaling in DLD-1 cells. Meanwhile, the 
phosphorylated β-catenin level, an indicator of β-catenin degradation in the 
cytoplasm, was significantly induced in cells treated by genistein (Figure 4.3B), 
which further confirmed that the WNT signal was down-regulated by genistein 
treatment.   
WNT antagonist sFRP2 expression in DLD-1 cells treated with genistein 
and 5-aza-cytidine  
sFRP2 has been demonstrated in previous studies to be silenced in 
colorectal cancers (37; 41; 90; 109). Quantitative PCR was conducted to analyze the 
difference of sFRP2 expression level among treatment groups. The sFRP2 
expression level in the genistein-treated cells increased six-fold over the level of 
the control cells (Figure 4.4). At the same time, 5-aza-cytidine, a DNA 
methyltransferases inhibitor, was used to treat the cells as the positive control for 
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DNA demethylation. A significant induction was also observed in the 5-aza-
cytidine-treated cells (Figure 4.4). Moreover, genistein treatment induced the 
sFRP2 expression to a level similar to the 5-aza-cytidine treatment, suggesting 
that genistein may restore sFRP2 expression through epigenetic means. 
Demethylation of the sFRP2 promoter by genistein treatment in DLD-1 cells 
To determine whether genistein induced sFRP2 expression through either 
demethylation or alteration of mRNA stability, an mRNA stability test was 
conducted on sFRP2 after genistein treatment. There was no difference in half 
life of sFRP2 mRNA between the genistein-treated cells and the control cells 
(data not shown), excluding the possibility that genistein increased sFRP2 mRNA 
levels by affecting its stability. Recently, it has been shown that sFRPs were 
silenced in colon cancer cells by hypermethylation of CpG islands in their 
promoter region (37; 41; 90). Methylation selective PCR was employed to detect 
changes in the methylation status of two regions of the sFRP2 gene in DLD-1 
cells treated with either 5-aza-cytidine or genistein. Methylation of a region in L7a 
gene was analyzed as a control to demonstrate the efficiency of bisulfite 
conversion and the loading quantity from each treatment.  During the bisulfite 
conversion reaction, the cytidine of a methylated “CpG” dinucleotide remains “C”, 
and every unmethylated cytidine will be converted to “U” and changed to “T” after 
the PCR process. Therefore, the methylation status of a given region is 
quantified after the selective PCR amplifications using MSP primers designed 
specifically for methylated (C) or unmethylated (T) nucleotides. In this study the 
MSP analysis showed that genistein-treatment decreased the methylation level 
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of both sFRP2 CpG regions by about 50%, in a manner similar to 5-aza-cytidine 
treatment (Figure 4.5). This result confirmed that genistein attenuates aberrant 
WNT signaling by up-regulating sFRP2 expression through demethylation of the 
silenced promoter. 
Discussion 
In this study, we present a novel mechanism by which genistein may 
bestow protection against colon cancer progression. We used human colon 
cancer cell line DLD-1 as an in vitro model to evaluate the ability of the soy 
isoflavone genistein to repress colorectal carcinogenesis. Our data demonstrate 
that genistein, at micro molar concentration: 1) restores sFRP2 expression level 
through demethylation at CpG islands in its promoter region; 2) attenuates 
accumulation of β-catenin in the nucleus; 3) promotes β-catenin phosphorylation; 
4) reduces cancer cell viability and proliferation; and 5) increases apoptotic cell 
numbers. Our finding that dietary genistein attenuates aberrant WNT signal has 
strong implication for colon cancer treatment.  
Cellular conditions that result in the under-expression of WNT inhibitive 
regulators including sFRPs, are indicative of abnormally functioning WNT 
signaling. The WNT signaling is intimately involved in many types of neoplasms 
by virtue of its positive effect on cell proliferation via β-catenin. There is strong 
evidence that nuclear β-catenin stabilization is highly correlated with cancer 
progression (115; 116; 117).  By binding to transcription factor TCF in the nucleus, 
nuclear β-catenin can trigger downstream gene transcription, which ultimately 
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influences cell proliferation and growth. Our observation showed that genistein 
treatment repressed colon cancer cell growth and elevated cell apoptosis. 
Therefore colon cancer development may be assuaged by dietary genistein 
intake.  Genistein’s mode of action is through lessening the nuclear accumulation 
of β-catenin by enhancing the gene expression of an antagonist sFRP2. It has 
been shown that re-expression of sFRP family members could attenuate 
aberrant WNT signaling and alleviate the growth promoting effects from 
constitutive WNT signaling (37). Therefore it is likely that genistein counteracts 
tumorigenic signaling pathways by suppressing anomalous WNT signaling 
through de-repression of the WNT antagonist sFRP2 and restoring sFRP2 
expression.  
It has been widely reported that some types of dietary components have 
anticancer functions provided by their demethylating abilities (10; 110).  Genistein, a 
natural isoflavone extracted from soy products, has epigenetic effects in prostate 
and breast cancer cells (4; 12).  We previously identified that genistein induced one 
of the WNT signals, the WNT5a, through promoter demethylation (13).  In the 
present study, we not only confirmed the demethylation effect of genistein, but 
also observed that the WNT antagonist sFRP2, which is silenced in colon cancer 
cells, has been epigenetically activated by genistein.  The genistein-induced 
activation of sFRP2 leads to attenuation of aberrant WNT signaling, resulting in 
the restriction of cancer cell growth.   
The concentration of genistein is a determining factor of its anticancer 
property. In colon cancer cell culture, genistein treatment ranging from 20-100 
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µmol/L significantly inhibited cell growth by the combination of reduced 
proliferation and increased apoptosis (99) Cytotoxicity of genistein in this cell 
model is estimated to be ~11 g/L (24.82 g/L for total isoflavone), equivalent to 
~40 mmol/L of genistein (66). Together with the dosage analysis performed in the 
DLD-1 cells in our laboratory, we applied 75 µmol/L of genistein in the current 
study and observed maximally inhibitory effect on cell growth. Furthermore, in 
vivo study with oral administration of genistein intake suggested the saturation 
level of genistein intake was about 50 ppm (118). The dosage we used equals to 
~20 ppm and was within the saturation level of intake. According to the study 
done by Busby et al., 40 µmol/L of plasma genistein was achievable by oral 
intake of 4 mg/kg purified genistein (in total of 8 mg/kg of isoflavone mixture (119)). 
Considering that intestine has the second highest genistein amount after oral 
intake (118), the surrounding environment of intestinal epithelial cells could be 
exposed to genistein concentrations at micro molar range. Thus, 75 µmol/L is a 
theoretically reachable concentration by oral administration of genistein.  Further 
in vivo experiments are needed to address the effects from genistein as seen in 
the current cell culture study. 
Based on this study we suggest that genistein, a soy-derived dietary 
component, confers anticancer effects through altering WNT signaling. This 
study provides the first evidence that sFRP2, which dysregulation is highly 
correlated with carcinogenesis, is a target of genistein.  In summary, genistein 
restores the expression of the WNT antagonist sFRP2 in colon cancer cells by 
modifying DNA methylation of the gene. Future elucidation of the molecular 
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mechanisms by which genistein modifies the epigenome will facilitate the 
development of diet-derived therapies that work to decrease colorectal cancer. 
  

















Figure 4.1  Genistein affects DLD-1 cell viability and proliferation. (A) Cell 
viability was analyzed by Trypan blue dye exclusion test after DMSO (Control) 
and genistein (75 µmol/L) treatment. Trypan blue-negative cells are considered 
viable cells. One hundred percent represents total number of cells (both Trypan 
blue negative and positive) in Control. Bars represent percentage of viable cells 
to total number of cells in Control.  (B) Cell proliferation was detected by WST-1 
assay. Higher levels of absorbance indicate higher proliferation.  Samples from 
two independent experiments were analyzed and presented as the means ± 
SEM. Asterisks (*) indicate statistical significance (p <0.05) compared to Control. 
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Figure 4.2  Induction of apoptosis in DLD-1 cells treated with genistein.  After 
treatment with DMSO (Control) or genistein (75 µmol/L), cells were dual-stained 
with Annexin-V FITC and PI, and subjected to flow cytometry analysis. (A) 
Representative dot plots from flow cytometry. Apoptotic cell population is shown 
in the lower right quadrants. (B) Quantitation of apoptotic cell numbers from flow 
cytometry analysis. The apoptotic rate is calculated from the total number of cells 
that passed through the flow cytometer. Data were analyzed and presented as 
the means ± SEM. Asterisks (*) indicate statistical significance (p <0.05) 
compared to DMSO control.   
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Figure 4.3  Western blot analysis of β-catenin protein level after genistein (75 
µmol/L) treatment. (A) Nuclear abundance of β-catenin. Nuclear extract was 
analyzed by Western blot using an antibody against total β-catenin. Top panel, 
representative blots from the Western blot analysis; lower panel, quantification of 
Western blot analysis. Lamin A was used as the loading control for nuclear 
extracts. (B) Phosphorylated β-catenin level in DLD-1 cells treated with genistein. 
Whole cell protein extract was analyzed using an antibody specifically against the 
Ser33/37/Thr41-phosphorylated β-catenin. Actin was used as the loading control. 
Samples from at least three independent experiments were analyzed and 
presented as the means ± SEM. Asterisks (*) indicate statistical significance (p 
<0.05) compared to DMSO control.     
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Figure 4.4  sFRP2 mRNA expression following DNA demethylation treatment. 
Real time RT-PCR was performed to detect the expression level of sFRP2 after 
either 5-aza-cytidine or genistein (75 µmol/L) treatment. L7a was used as the 
internal control. Samples from at least three independent experiments were 
analyzed and presented as the means ± SEM. Asterisks (*) indicate statistical 
significance (p <0.05) compared to DMSO control. 
 
  
	   40	  
 
 
Figure 4.5  Methylation selective PCR (MSP) of sFRP2 and L7a methylation 
levels. Genomic DNA was treated with sodium bisulfite and then amplified and 
detected by real time PCR using methylated CpG-specific or unmethylated CpG-
specific primers. (A) Illustration of two CpG islands in the sFRP2 promoter 
region. Numbers on the top of the sequence sections represent the regions 
selected for CpG island identification by the program located at 
www.ebi.ac.uk/emboss/cpgplot/. The CpG islands identified by the program are 
in the boxed, shaded regions. Numbers located at the bottom of the sequence 
represent the primer locations for the MSP analysis. (B) MSP analysis of sFRP2. 
MSP using L7a (U) was conducted as a control (left panel). The methylation level 
of sFRP2 after either genistein or 5-aza-cytidine treatment was analyzed using 
primers that detect the methylated CpG at the two genomic regions (-391/-324 
and +136/+225). Data are plotted as the ratio to the level of methylation in the 
control samples.  Data were analyzed and presented as the means ± SEM. 
Asterisks (*) indicate statistical significance (p<0.05) compared to Control.  
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Chapter 5: Genistein, A Soy Isoflavone, Prevents Azoxymethane-induced 
Upregulation of WNT/β-catenin Signaling and Reduces Colon Pre-neoplasia 
in Rats 
Introduction  
Evidence from epidemiological studies has demonstrated that the intake of 
soy products reduces colon cancer risk (53; 54; 120; 121), and this protective effect 
has been shown to be partially derived from genistein, a soy isoflavone (61).  
Aberrant crypt foci (ACF), which are pre-neoplastic lesions in the colon, can be 
induced by carcinogens such as azoxymethane (AOM) in rat models (122; 123).  To 
better understand the chemo-preventive potential of dietary compounds, AOM-
induced ACF development in rats was utilized to model colon carcinogenesis (124; 
125).  By analyzing AOM-induced ACF in rats or mice, soy products containing 
isoflavones have been shown to reduce precancerous colon lesions (126; 127).  Soy 
protein isolate in the diet also reduced colon tumor incidence in male Sprague-
Dawley rats (65).  Therefore, in the present study, we used a soy protein isolate 
(SPI) diet containing genistein as a positive control for the genistein diet and 
investigated the effect of genistein on early stages of colon cancer development 
in an AOM-induced rat model.   
Timing and exposure duration are critical for the effective prevention of 
colon cancer development by genistein.  Genistein diets (75 or 150 mg/kg) fed to 
F344 rats pre- and post- AOM induction contributed to decreased ACF (128).  In a 
more recent study, lifelong feeding (from gestation to 26 wk of age) of a soy diet 
containing 182 mg/kg of genistein reduced AOM-induced colon tumor burden 
and size (66).  However, a soy diet containing 1200 mg/kg of genistein fed to 1 
mo, 11 mo and 22 mo old female F344 rats one week before AOM injection, 
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showed no protection against the formation of ACF in all age groups (129).  
Therefore, we used the rat model of lifelong-genistein exposure, including the 
maternal period, with a moderate level of dietary genistein to investigate the 
protective role of genistein in colon cancer development.  
Colon cancer isr one of the most prevalent malignancies worldwide (57; 98).  
Increasing evidence has shown that WNT/β-catenin signaling is closely involved 
in normal colon development, as well as in the carcinogenic process (35; 87; 88; 130).  
Briefly, WNT signaling is initiated when a WNT protein, such as WNT1, binds to 
its membrane receptor (105).  The WNT signal is passed to β-catenin through a set 
of cytoplasmic components, including GSK3β, Axin1 and APC.  By forming a 
complex with TCF/LEF in the nucleus, β-catenin then triggers the expression of 
WNT target genes, such as Cyclin D1 and c-Myc, which are critical for 
proliferation of normal intestinal cells (28).  Once WNT signaling is disturbed, the 
intestinal cells may lose control of proliferation, leading to a greater chance of 
tumorigenesis (35), and blockage of Wnt1 has been proposed to promote 
apoptosis in colon cancer cells (131).  WNT/β-catenin signaling promotes cell cycle 
progression by activating its downstream genes Cyclin D1, and c-Myc (105).  AOM 
induction enhances the level of β-catenin in the colon (125; 132), and an elevated 
level of nuclear β-catenin has been observed in most cases of colorectal cancer 
(5; 130).  Thus, we used nuclear β-catenin abundance as an indicator of colon 
abnormality.  WNT/β-catenin signaling is regulated by several WNT antagonists, 
including the secreted frizzled-related protein Sfrp1, Sfrp2, and Sfrp5 (33).  Wnt5a 
has also been reported to be an inhibitor of WNT/β-catenin signaling (133), and the 
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inactivation of WNT antagonists along with aberrant WNT signaling was 
observed in colon cancer (37).   
In the current study, we focused on determining the effect of genistein on 
preventing the development of colon pre-neoplasia.  In particular, we aimed to 
discover the mode of action of genistein on modulating the WNT/β-catenin 
signaling pathway both before and after exposure to a carcinogen.  Our findings 
provided the first clue that lifelong exposure to genistein reduced the frequency 
and severity of pre-neoplastic lesions in colon by suppressing carcinogen-
induced upregulation of WNT/β-catenin signaling.  Therefore, dietary genistein 
may provide promising chemopreventive properties against the development of 
colon cancer.  Furthermore, by using this model, we discovered that the 
expression of marker genes in the WNT/β-catenin signaling pathway were 
closely correlated with the colon neoplasia and could serve as a tool for the early 
detection of colon abnormality. 
 
Experimental Methods 
Animals and Diets.  Timed-pregnant Sprague-Dawley rats (Charles River 
Laboratories) were obtained on d 2 of gestation and fed one of three isocaloric 
diets throughout the 3-wk gestation and 4-wk lactation periods (Figure 5.1).  The 
diets were modified according to the AIN-93G diet formula (134) with corn oil as 
the fat source (Table 5.1).  The diets were: 1) CTL (casein protein), 2) SPI (soy 
protein isolate, NutroBio.com), and 3) GEN (CTL plus 140 mg/kg genistein).  
Diets were balanced and matched for content of protein, carbohydrate, fat, amino 
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acids, vitamins, and minerals.  The amount of genistein in the soy protein isolate 
used in the SPI diet was analyzed by HPLC to be 0.705± 0.025 mg/g (total 
aglycone equivalents, see ref. by Andrade et al for details in HPLC analysis (135)).  
After formulating the SPI diet using the soy protein isolate as the only protein 
source at 20% w/w level, the final genistein level in the SPI diet was confirmed by 
HPLC (131±17 mg/g).  When making the GEN diet, genistein content in the GEN 
diet was matched to the genistein level in the SPI diet (aglycone equivalent).  
Genistein was purified from soy, characterized, and kindly provided by Dr. 
William Helferich at the University of Illinois.  All groups of rats had free access to 
food and water and were kept individually in standard polycarbonate cages in a 
humidity- and temperature-controlled room.  All procedures were approved by 
the Institutional Animal Care and Use Committee at the University of Illinois at 
Urbana-Champaign.  At d 24, the male pups from each group were weaned and 
maintained on the same diet as their mother until they were killed at the various 
time points. The first sampling occurred when the offspring were 7-wk old (CTL, 
n=6, SPI and GEN, n=8) and the samples were used to examine the pre-
induction gene profile.  The remaining rats were injected with AOM (15 mg/kg 
BW) at 7-wk and 8-wk of age.  Six wk later, the AOM-induced rats were killed 
(n=8 per treatment group) by CO2 asphyxiation and colon tissues were collected 
for all subsequent analyses.  
 
Colon Tissue Sampling.  At 13-wk of age, all rats were killed by CO2 
asphyxiation.  Descending colons were carefully removed, slit open 
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longitudinally, and washed twice with ice cold PBS.  The first 1/3 of the 
descending colon section was cut off and then stapled onto transparent film and 
then was subjected to 10% formaldehyde fixation for 24 h followed by 10% 
ethanol fixation.  After staining by 0.1% methylene blue, samples were subjected 
to ACF counting as described below.  The epithelial cells were scraped from the 
remaining 2/3 of the section and immediately frozen in liquid nitrogen and stored 
in -80 °C for further gene and protein analysis. 
 
ACF identification and quantification.  The frequency and multiplicity of ACF 
were determined under a dissection microscope.  The identification criteria for 
ACF were as follows: two to three times larger than normal crypts, 
microscopically elevated, had slit-like openings, had thicker epithelial linings, 
which were stained darker than normal crypts, and had larger pericryptal zones 
(136).  The total number of aberrant crypts in the sampled descending colons was 
counted by a single blind method, and then the average number of aberrant 
crypts of the colon, with no discrimination on the multiplicity, was determined as 
the mean of total aberrant crypts/length of section (frequency per cm).  The crypt 
multiplicity was described as N=1, N=2, and N=3 or above for the number of 
crypt(s) per foci (For examples, see Figure 5.2A).  The mean of ACF/cm with 
different multiplicity was determined accordingly.   
 
Histology and Immunofluorescent staining.  Fixed colon samples were 
embedded in paraffin prior to sectioning.  All sections were then stained with 
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hematoxylin and eosin (H&E) for histological analysis.  Slides were 
deparaffinized and blocked with IT signal FX (Invitrogen), and then incubated 
with either anti-β-catenin, (1:250, Cell Signaling Technology), anti-Wnt5a, or anti-
Sfrp2 antibodies (1:200, Santa Cruz Biotechnologies) at room temperature for 
3.5 h.  After washing with 1x PBS, slides were incubated with a goat-anti-rabbit 
Alexa Fluor 647 labeled secondary antibody (1:200, Invitrogen) at room 
temperature for 45 min, and then rinsed in 1x PBS again.  All slides were 
incubated in Hoechst (10 µg/mL, Invitrogen) at room temperature for 15 min.  
After washing with 1x PBS, slides were mounted and dried in the dark for 24 h at 
room temperature.  Pictures were taken using the Axiovert 200M microscope 
(Zeiss).   
 
Quantitative RT-PCR.  Scraped colon tissues were ground in liquid N2 and 
treated with TRI Reagent (Sigma-Aldrich).  Total RNA was isolated according to 
the manufacturer’s instructions, and RNA concentrations were measured by a 
Spectrophotometer (BioRad SmartSpec Plus).  cDNA was synthesized from RNA 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA) in a Thermal Cycler 2720 (Applied Biosystems).  In each 
reaction system, 2 µg of total RNA were used in a 20 µL mixture containing 1× 
RT buffer, 4 mmol/L dNTPs, 1× RT random primers, and 2.5 U/µL MultiScribe 
Reverse Transcriptase.  cDNA synthesis was performed using the following 
program: 25 °C for 10 min, 37 °C for 2 h, and 85 °C for 5 sec.  Synthesized cDNA 
was then analyzed by PCR in a 7300 thermal cycler (Applied Biosystems).  In 
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each reaction, 25 ng of synthesized cDNA was used in a 20 µL volume 
containing 10 µL of SYBR Green master mix (2x, Applied Biosystems) and 0.25 
µmol/L of each primer.  PCR was performed using the following program:  95 °C 
for 10 min, followed by 35 cycles of 95 °C for 15 sec and 60 °C for 1 min.  After 
PCR, melting curves were acquired stepwise from 55 to 95 °C to ensure that a 
single product was amplified in the reaction. L7a, the gene encoding a ribosomal 
protein, was used as an internal control for normalization of individual values. 
The primers used in this study are listed in the Table 5.2.   
 
Protein isolation and immunoblotting.  For obtaining nuclear extracts, 100 mg 
of scraped colon tissue was pulverized in liquid N2, washed and dislodged twice 
with ice-cold PBS, and collected by centrifugation at 500 × g.  Cell pellets were 
lysed with fresh lysis buffer (20 mmol/L HEPES pH 7.9, 10 mmol/L sodium 
chloride, 1.5 mmol/L magnesium chloride, 0.2 mmol/L EDTA, 20% glycerol (v/v), 
1 mmol/L DTT (Roche, USA), 1 mmol/L PMSF (Sigma, USA), 1× protease 
inhibitor cocktail (Roche, USA), and 0.1% Igepal CA-630 (v/v) on ice for 15 min 
and centrifuged again.  Lysis was repeated for the resuspended pellet, followed 
by centrifugation at 500 × g. The precipitates were then incubated with fresh 
nuclear extraction buffer (20 mmol/L HEPES pH 7.9, 400 mmol/L sodium 
chloride, 1.5 mmol/L magnesium chloride, 0.2 mmol/L EDTA, 25% glycerol (v/v), 
1 mmol/L DTT, 1 mmol/L PMSF, 1× protease inhibitor cocktail) at 4°C for 30 min.  
Nuclear protein extracts were then collected from the supernatants after 
centrifugation at 12,000 × g.  Protein concentration was determined by Lowry 
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assay.  For Western blot analysis, 30 mg of nuclear protein was size-fractionated 
on a 12% Tris–HCl polyacrylamide gel.  Immunoblotting was performed by using 
a 1:1000 rabbit polyclonal antibody against β-catenin (Cell Signaling 
Technology), 1:1000 rabbit polyclonal antibody to detect Lamin A (Santa Cruz 
Biotechnology), and a 1: 10,000 goat-anti-rabbit HRP-conjugated secondary 
antibody.  Nuclear protein Lamin A was used as an internal loading control for 
nuclear extract (39; 137).  The membranes were exposed to the enhanced 
chemiluminescence reagent SuperSignal West Dura (Pierce), and the signals 
were detected and quantified using ChemiDoc XRS imaging system (Bio-Rad).   
 
Statistical analysis.  Differences in body weight and food intake between 
groups were analyzed by using repeated-measures one-way ANOVA (SAS 
Institute Inc., Cary, NC).  Results were reported as means ± SEM.  Differences 
were considered significant at P<0.05.  By performing regression analysis (Data 
Analysis for Excel2010), the possible relationships between the total number of 
ACF/cm and the expression level of Wnt genes, including Wnt5a, Sfrp1, Sfrp2 
and Sfrp5 were tested, as well as the relationship between the nuclear β-catenin 
level and the total number of ACF/cm.  A linear relationship was considered 
significant at P<0.05.  A box plot was used to analyze the frequency of total 
ACF/cm.  The lower line in the box represents Q1, the top point of the lower 
quartile; the middle line in the box represents Q2, the median point; and the 
upper line in the box represents Q3, the lowest point of the upper quartile. The 
smallest value was calculated as Q1 − 1.5 × (Q3 – Q1) and is represented as the 
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end point of the lower whisker; the largest value is calculated as Q3 + 1.5 × (Q3 – 
Q1) and is represented as the end point of the upper whisker.  The slope of 
regression lines of ACF incidence on the stage of ACF (N) between either SPI or 
GEN and CTL was calculated by ANCOVA (Table 5.1).  The ACF counting 
results were analyzed by one-way ANOVA.  Results from immunoblotting and the 
quantitative real-time PCR analysis were analyzed using two-way ANOVA with 
interactions with diet and AOM-induction as main effects.  Letters were assigned 
by the post-hoc Tukey test.  Bars with different letters were differ at P<0.05.  
Results were reported as means ± SEM.  Differences were considered significant 




All rats survived the full treatment period.  There was no difference in body 
weight among the dietary groups during the trial (P = 0.30), but rats fed the SPI 
diet gained more weight following AOM injection than the other two groups 
(Figure 5.3).  After AOM injection, rats fed SPI had higher food intake compared 
to CTL or GEN, while there was no difference between CTL and GEN groups.  
No rats were observed to have behavioral changes or stress responses before or 
after AOM induction.  All rats developed aberrant crypts after AOM treatment, 
and the highest number of aberrant crypts/aberrant foci was N=3.  There were no 
morphological differences observed in descending colons among the three 
dietary groups after AOM induction (Figure 5.4) 
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Genistein inhibited ACF in the descending colon 
At the end of the study period (6-wk after AOM induction), eight rats from 
each dietary group were killed for ACF identification and quantification (see a 
representative image of ACF in Figure 5.2A).  Compared with CTL diet, GEN 
diet significantly reduced the total number of aberrant crypts/cm (P=0.02, Figure 
5.2B).  Rats fed the SPI diet also tended to have a decreased number of 
aberrant crypts/cm.  Additionally, GEN and SPI groups did not differ in total 
aberrant crypts/cm.   
The total aberrant crypts were grouped into three subcategories according 
to the number of crypts (N) per foci: N=1; N=2; and N=3.  A higher N value 
represents a more severe crypt abnormality.  All rats in all three diet groups have 
been induced with ACF with N=1 (100%).  The slope of the regression line of 
ACF incidence on N was significantly different between CTL and SPI, suggesting 
that compared to the CTL group, fewer rats in SPI group developed ACF with 
N=2 and N=3.  The slope of the regression line of GEN was not significantly 
different from that of CTL, but there was a significant effect from N (P=0.02; 
Table 5.3).  Further analysis of multiplicity showed that there was a significant 
diet effect on the number of ACF with N=3 per cm of descending colon (P=0.038, 
Table 5.4).  In particular, the GEN diet significantly decreased the number of 
ACF with N=3 /cm of colon compared to the CTL diet (P=0.019, Table 5.4). 
 
	   51	  
Genistein prevented AOM-induced nuclear β-catenin accumulation and 
suppressed Cyclin D1 and c-Myc expression in the descending colon 
The role of WNT/β-catenin signaling was examined by western blot and 
immunofluorescent staining.  The mRNA levels of WNT/β-catenin downstream 
genes were evaluated by real-time PCR.  Overall, there was a significant diet 
effect on the abundance of nuclear β-catenin (P=0.008) and the expression of c-
Myc (P=0.02).  Additionally, AOM-induction significantly impacted nuclear β-
catenin and the expression of Cyclin D1 (P<0.0001, Figure 5.5C).  There was a 
significant interaction (P<0.05 for nuclear β-catenin and c-Myc and P=0.06 for 
Cyclin D1) between diet and AOM-induction because during normal development 
at 7-wk, prior to the AOM injection, the nuclear accumulation of β-catenin and the 
expression of Cyclin D1 and c-Myc in the descending colon did not differ among 
the diet groups (pre-AOM, Figure 5.5A, 5.5B and 5.5C) but post-AOM, nuclear 
β-catenin and c-Myc expression were significantly repressed in the SPI and GEN 
groups.  In particular, the nuclear accumulation of β-catenin was reduced to the 
pre-AOM level.  Cyclin D1 was significantly lower in the GEN group when 
compared to CTL.  Moreover, by using immunofluorescent staining, we 
confirmed the result from the western blot analysis showing that the level of β-
catenin protein in the descending colon of CTL rats was higher than that in either 
SPI or GEN rats (Figure 5.6).  Additionally, regression analysis indicated that the 
decrease in total aberrant crypts/cm in all animals was correlated with the 
attenuation of nuclear β-catenin accumulation following AOM injection (R2=0.74, 
P=0.003).   
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Wnt5a and Sfrp expression profiles were affected by genistein 
The possible relationship between the decrease of total ACF and the 
regulation of WNT gene expression by SPI and GEN was tested by RT-PCR and 
immunofluorescent staining of the colon sections.  In general, AOM-induction and 
diet affected the expression of Wnt1 (AOM, P=0.007, diet, P=0.84), Sfrp1 (AOM, 
P=0.002, diet, P=0.07), Sfrp2 (AOM, P<0.0001, diet, P=0.06) and Sfrp5 (AOM, 
P=0.005, diet, P=0.08).  The interaction between AOM-induction and diet for 
Wnt5a expression (P=0.02) was due to the fact that while there was no diet effect 
pre-AOM, the post-AOM SPI and GEN groups were significantly lower than the 
CTL.  The expression levels of Wnt1, Wnt5a, Sfrp1, Sfrp2 and Sfrp5 in the 
descending colon were not different among the dietary groups at 7-wk, prior to 
AOM injection (Figure 5.7).  However, at 13-wk of age, AOM-induction up-
regulated the expression levels of Wnt1, Wnt5a, Sfrp1 and Sfrp5 significantly in 
the CTL group when compared to the other dietary groups.  Notably, the 
expression level of Wnt5a, Sfrp2 and Sfrp5 returned to be similar to or even 
below that of the pre-AOM values in both SPI and GEN groups, while Sfrp1 was 
significant lower in the GEN group only.  Moreover, the repression of WNT-
associated gene expression was correlated with the decrease of the total number 
of aberrant crypts/cm (Wnt5a, R2=0.31, P=0.017; Sfrp1, R2=0.46, P=0.002; 
Sfrp2, R2=0.65, P<0.001; Sfrp5, R2=0.50, P=0.001).  However, Wnt1 expression 
did not respond to either SPI or GEN diet (Figure 5.7A).  By conducting 
immunofluorescent staining using currently available antibodies, we further 
	   53	  
showed that the protein levels of Wnt5a and Sfrp2 were also repressed by the 
SPI and GEN diets (Figure 5.7B, 5.7C).  Overexpression of Wnt5a and Sfrp2 
protein after AOM induction was clearly visible within the colon crypts in CTL 
animals, while both SPI and GEN diets considerably reduced the signals of the 
two proteins (Figure 5.7B, 5.7C).   
 
Discussion 
Using an in vivo model, in this paper, we report that a lifetime exposure to 
genistein reduces the incidence and frequency of colon pre-neoplasia in the 
descending colon of AOM-induced rats.  We suggest that this suppression 
occurs through minimized level of WNT/β-catenin signaling to the same as or 
lower than that prior to AOM injection.   
 Previous studies have revealed conflicting effects of the intake of soy 
isoflavones on AOM-induced ACF formation in rat colon.  Various factors 
contribute to the differences, including the duration of exposure.  In the current 
study, we analyzed the effect of a lifelong dietary exposure of genistein in both 
pre- and post-carcinogen periods, which included both maternal periods of 
gestation and lactation.  We showed that dietary genistein decreased the 
frequency and severity of the ACF when examined at the early stage of colon 
pre-neoplastic development.  Specifically, genistein reduced the number of ACF 
with N=3, suggesting that genistein prevented colon crypts from becoming 
abnormal.  Although rats in the current study and in the report by Raju et al 
(2009) (66) had similar exposure times to the diets before AOM induction, we 
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aimed to define the effect of genistein on the relatively early stage of colon 
cancer development.  Raju et al. analyzed ACF at 26-wk after carcinogen 
exposure and observed colon tumor formation, which may explain why they 
observed a repressive effect of soy isoflavones on colon tumor formation, but not 
on ACF.   
The effect of genistein on colon cancer development differs with the 
dosage and timing of exposure.  In the current study, we focused on testing the 
consequences of a maximal genistein exposure time.  Therefore, we defined the 
lifelong period as occurring from d 2 of gestation until after carcinogen induction.  
Meanwhile, we used a relevant dosage of genistein which is achievable by soy 
consumption.  Application of the above-mentioned approach may be the reason 
for the protective effects observed in our study compared to those published 
previously.  For instance, Gee et al. (2000) showed that when soy isoflavones 
were administered only immediately before the AOM induction, with a 
comparatively shorter exposure time than ours, both pure genistein (250 mg/kg) 
and soy protein isolate (250 mg of genistein/kg) triggered 3- or 2-fold-increase of 
ACF, respectively, in the distal colon (138).  Moreover, Rao et al. (1997) reported 
that a postnatal-only intake of 250 mg of genistein/kg of diet promoted both 
noninvasive and total adenocarcinoma multiplicity (139).  Another study reported 
that a high dose feeding of 2 g soy isoflavone/kg of diet (supplemental dosage of 
1200 ppm of genistein) enhanced sensitivity to AOM in older female rats (129).  
Compared with the administration of 250 ppm or 1200 ppm of genistein in these 
studies, our SPI and GEN diets contained less genistein (140 ppm), therefore 
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making it a model more relevant to dietary intake level (140).  Additionally, we fed 
rats with the same diet throughout their lifetime.  A similar animal model was 
previously used by another group (141), who reported inhibitory effects from the 
lifelong soy protein consumption on tumor incidence.  In the current study, in 
addition to confirming the protective effect of SPI, we intended to use the SPI diet 
as a positive control to specifically investigate the effects of genistein as a major 
component of soy isoflavones.  Our finding highlighted that lifelong intake of 
genistein reduced the frequency of ACF with N=3.  SPI diet, which contained a 
mixture of other dietary isoflavones and soy proteins, showed less of a protective 
effect than genistein alone.   
Our study provides the first clue for the potential mechanism by which 
dietary soy prevents colon neoplasia, which is proposed to occur through the 
regulation of WNT/β-catenin signaling.  WNT/β-catenin signaling plays an 
important role in maintaining intestinal homeostasis, as well as promoting colon 
cancer development (5; 87).  WNT signaling is a major driving force in the renewal 
process of the epithelium, which is critical for intestinal development (35; 87; 142; 143).  
On the other hand, its hyper-activation, marked by abnormal accumulation of 
nuclear β-catenin, disrupts normal cellular events and leads to carcinogenesis 
(144).  Our results demonstrate that during colon development, prior to AOM 
injection, the nuclear accumulation of β-catenin was not different among dietary 
groups, indicating normal WNT signaling activity, which was also confirmed by 
the fact that the expression levels of Cyclin D1, c-Myc, and the WNT-associated 
genes tested were not different among the dietary groups.  Therefore, 
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stabilization of β-catenin is critical for colon tumorigenesis (88; 105).  Data from the 
current study showed that AOM induction resulted in tissue-wide abnormality in 
WNT/β-catenin signaling before actual tumor formation.  Therefore, in the current 
study, we validated the use of nuclear β-catenin to predict the carcinogenic 
potential of rat colon by AOM in different groups, and as a marker to evaluate the 
protective effect of genistein-containing diets against colon carcinogenesis.   
To investigate the involvement of WNT/β-catenin at the early stage of 
colon cancer development, we conducted an AOM-induced animal study with a 
non-hyperplasia end point, which was confirmed by histological analysis.  Using 
structurally intact colon samples, we examined the nuclear distribution of β-
catenin protein and its localization within the colon crypt, as well as the 
expression of WNT-related genes in the descending colon.  Instead of only 
investigating the abnormal areas of the colon by limiting our analysis to the ACF, 
we considered the abnormality of β-catenin in the entire colon epithelia as a 
potential marker for colon carcinogenesis.  After AOM induction, we observed 
that β-catenin was induced throughout the descending colon epithelia in the CTL 
group but returned to the same level as the pre-AOM values in the SPI and GEN 
groups, suggesting that the hyper-activation of WNT signaling induced by AOM 
was prevented by SPI and GEN diets.  Moreover, the expression of oncogenic 
WNT/β-catenin downstream genes Cyclin D1, and c-Myc were also inhibited, 
confirming that SPI and GEN protected rats against AOM-induced aberrant WNT 
signaling.  Interestingly, the expression of Wnt1 was upregulated in CTL, SPI and 
GEN groups when compared to the pre-AOM period, and without differences 
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among the three diets.  The upregulation of Wnt1 expression indicates that a 
subsequent activation of WNT signaling was potentially induced by AOM.  
However, the critical marker of WNT signaling, nuclear β-catenin, was reduced in 
SPI and GEN groups, indicating the overall protection by SPI and GEN from 
carcinogenesis by AOM-induction.   
Using colon cancer cells, we previously identified that genistein treatment 
suppressed the overactivated WNT signaling pathway by upregulating the 
expression of WNT antagonists, including Sfrp2 and Wnt5a, thus inhibiting 
cancer cell growth (Zhang and Chen 2011 (39), Wang and Chen 2011 (49)).  The 
mechanism may be that when the Wnt is upregulated in cancer cells, genistein 
treatment induces downregulation of this malignant signaling pathway under this 
situation by upregulation of the WNT antagonists including Wnt5a and Sfrp2.  In 
the current study, we showed that at the early stage of colon cancer 
development, the repressed WNT/β-catenin signaling by SPI and GEN did not 
result from the upregulation of WNT antagonists tested, including Sfrp1, Sfrp2, 
Sfrp5 and Wnt5a.  A possible explanation for our observations from the in vivo 
animal model is that when administered before tumorigenesis, as oppose to the 
in vitro cancer cell model, SPI and GEN can keep WNT/β-catenin signaling low, 
thus rats fed with SPI and GEN do not require the same amount of gene 
expression of WNT antagonists as those fed a CTL diet to counteract the 
carcinogen-induced aberrant WNT/β-catenin activity.  Further studies need to be 
conducted to reveal which precise steps and components of WNT/β-catenin 
signaling are directly affected by genistein.  
	   58	  
As a predominantly expressed estrogen receptor in the colon (145), ER-β 
plays an important role in colon tumorigenesis (146).  Soy isoflavones have been 
reported as a preferred ligand to estrogen receptor-beta (ER-β) (147; 148).  
However, the interactions between soy isoflavones and ER-β during colon 
carcinogenesis are less studied.  In established colon cancer cell line DLD-1, ER-
β has been shown to be responsible for soy isoflavone-mediated growth 
suppression (100).  Similarly, rats fed diets containing soy isoflavones had higher 
level of ER-β in the developed tumors (66).  On the other hand, a study in which 
the relationship between the expression of ERβ and ACF formation was 
examined, has demonstrated that feeding of soy isoflavones did not affect the 
expression of ERβ in the colon among all age groups (129).  Similarly, we 
examined the expression of ERβ in the descending colon epithelium where most 
of the tissue was still in normal condition without developing ACF, thus we did not 
observe any dietary or AOM effect on the expression of ERβ.  Moreover, we 
conducted this study at ACF stage of tumorigenesis without any tumor formation 
whereas others showed most change of ERβ in the colon tumor or colon cancer 
cells.  It is possible that the ERβ would be altered by the diet at a later stage of 
carcinogenesis with tumor formation.  In a report by Bises et al, difference in 
response to soy diet between male and female mice was noticed (149).  Only 
female mice fed soy diet showed ~20% increase in ERα mRNA expression in 
ascending colon and moreover, soy diet did not affect the expression of ERβ in 
either sex (149).  The possibility of gender-specific response to genistein and/or 
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soy diets will be further explored by examining both female and male rats fed soy 
diets after AOM induction.   
Overall, our results demonstrate that the attenuation of nuclear β-catenin 
accumulation and WNT-related gene expression were strongly correlated with 
the decrease in the number of total ACF/cm of colon, indicating that genistein 
produced a protective effect and kept WNT/β-catenin signaling low when rats 
were exposed to a carcinogen.  Taken together, our findings indicate that lifelong 
intake of genistein may be protective against a carcinogenic load by preventing 
the over-activation of WNT/β-catenin signaling, and this leads to a decreased risk 
of colon tumorigenesis.   
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Tables 




      Diet 
 CTL SPI GEN 
Protein source, % weight Casein, 18 Soy protein isolates, 18 Casein, 18 
Fat (corn oil), % weight 7 7 7 
Carbohydrate, % weight 64.7 64.7 64.7 
Fiber, % weight 5 5 5 
Metabolizable energy (Kcal/g) 3.97 3.97 3.97 
Genistein (mg/kg aglycone 
equivalents) 
0 ~140 140 
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Table 5.3 Effect of soy protein isolate and genistein on ACF incidence1 
ACF incidence,  
No. of rats (n=8) 
Diet N=1 N=2 N=3 P value 
to CTL 
 CTL 8 8 7  
SPI 8 6 4 0.03 
GEN 8 7 5 0.13 	  
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	   ACF Incidence indicates the number of rats that developed ACF with the 
indicated stage (N=1, N=2, and N=3).  P value is the difference of the slope of 
regression line compared to CTL.  Letter n indicates sample size.  Letter N 
represents the number of aberrant crypts per foci.	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Table 5.4 Effect of soy protein isolate and genistein on ACF frequency 1 	  
Frequency, number of 
ACF per cm of colon 
(n=8) 
Diet N=1 SE N=2  SE N=3 SE 
 CTL 1.93a 0.58 1.72a 0.34 0.85a 0.25 
 SPI 2.92a 0.58 1.25a 0.41 0.38a,b 0.21 
 GEN 1.85a 0.37 1.69a 0.84 0.28b 0.11 	  
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Data are means ± SE.  Letter assignments were done by Tukey Test.  Means of 
frequency in a column with different letters are significantly different (P<0.05).  
Letter n indicates sample size.  Letter N represents the number of aberrant crypts 
per foci.   
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Figures 
 
Figure 5.1 Experimental design.  Pregnant Sprague-Dawley rats (F0) were 
separately fed CTL diet (0 mg of genistein /kg of diet), SPI diet (containing 140 
mg of genistein /kg of diet), or genistein diet (140 mg of genistein /kg of diet) 
throughout gestational and lactating periods.  After weaning, the male pups (F1) 
were continuously exposed to the same diet as their mother.  AOM injections 
were performed once a week for 2 wk at wk 7.  The initial sampling was 
performed before AOM injection at 7 wk.  ACF data were collected at 13 wk.  
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Figure 5.2 (A) A representative picture was taken after methylene blue staining.  
Circled areas represent examples of normal crypts, ACF with N=1, N=2 and N=3 
of crypt(s) per foci. (B) The box plot represents the number of total aberrant 
crypts per length of descending colon in 13-wk-old, AOM-treated rats fed a CTL, 
SPI or GEN diet.  Means without a common letter differ, P<0.05.   
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Figure 5.3 Body weight (g) of offspring rats fed on the control (CTL, 0 mg/kg of 
genistein), soy protein isolates (SPI, 140 mg/kg of genistein) and genistein (GEN, 
140 mg/kg of genistein) diet. Data are means±SEM. 
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Figure 5.4 Representative H&E staining of colon sections. The depth of crypt 
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Figure 5.5 Nuclear β-catenin abundance and WNT/β-catenin downstream 
gene expression.  Nuclei were extracted from scraped descending colons of rats, 
and protein levels were assessed by immunoblotting.  (A) Representative blots of 
β-catenin and Lamin A from Western blot analysis.  (B) Quantification of western 
blot analysis.  Lamin A served as the loading control for nuclear extracts.  
Samples from three rats in each dietary group were analyzed and presented as 
the means ± SEM.  (C) The expression levels of Cyclin D1 and c-Myc were 
analyzed by quantitative real-time PCR.  Samples were collected from CTL (npre-
AOM=6; npost-AOM=8), SPI (npre-AOM=8; npost-AOM=8), and GEN (npre-AOM=8; npost-
AOM=8) diets.  ≠ represents effect of AOM-induction, P<0.05.  Means without a 
common letter differ, P<0.05.     
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Figure 5.6 β-catenin distribution in the descending colon after AOM-induction.  
An anti-β-catenin antibody was used for immunofluorescent staining of β-catenin 
in colon sections (red).  Hoechst was used for staining of nuclei (blue).  Scale: 50 
µm.   
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Figure 5.7 Expression profiles of WNT-related genes in the descending colon.  
Samples were collected from rats fed CTL (npre-AOM=6; npost-AOM=8), SPI (npre-
AOM=8; npost-AOM=8), and GEN (npre-AOM=8; npost-AOM=8) diets.  (A) The mRNA 
expression levels of Wnt1, Wnt5a, Sfrp1, Sfrp2, and Sfrp5 were analyzed by 
quantitative real-time RT-PCR.  Data are presented as means ± SEM.  ≠ 
represents effect of AOM-induction, P<0.05.  Means without a common letter 
differ, P<0.05.  (B) and (C) Immunofluorescent staining of Wnt5a and Sfrp2 in 
colon sections of post-AOM rats (red).  Hoechst was used for staining of nuclei 
(blue).  Anti-Wnt5a and anti-Sfrp2 antibodies were used for the staining of Wnt5a 
and Sfrp2 proteins.  Scale: 50 µm.   
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Chapter 6: DNA Methylation and Histone Modifications of Wnt Genes by 
Genistein During Colon Cancer Development 
Introduction 
Epigenetic modulations such as DNA methylation and histone 
modifications closely orchestrate the transcriptional activity of genes, and specific 
epigenetic structures are required for maintaining the normal function of cells (1).  
Insufficient control of the epigenetic modifications activates oncogenes and 
deactivates tumor suppressor genes, leading to the development of various 
cancers (21).  Colon cancer has recently been reported to occur through the 
accumulation of aberrant DNA methylation (3) and disruption of histone codes 
(150).  Abnormal DNA methylation was detected in the normal-appearing mucosa 
at the early stage of colon carcinogenesis (3).  Global hypomethylation results in 
chromosome instability and activation of oncogenes (22; 23; 151; 152).  Changes of 
the methylation intensity of the promoter-CpG islands, which are regions rich in 
CpG dinucleotide, alter the expression level of key tumor suppressor genes (24).   
In addition to DNA methylation, histone modifications are considered as 
critical regulators in mediating gene activity as well.  Acetylation, methylation and 
phosphorylation at specific residues of histones such as Lys 4, Lys 9 and Ser 10 
provide chemical driving forces for chromatin configuration, preventing or 
allowing the initiation of gene transcription (25; 153).  Increase in histone 
deacetylase such as HDAC3 in the nucleus is associated with the reduction of 
histone acetylation (154).  Moreover, the crosstalk between DNA methylation and 
histone modifications has been of great interest recently.  Methylation of histone 
H3K9 has been shown to direct DNA methylation (155).  On the other hand, DNA 
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methylation could also affect histone methylation (156; 157).  It has been 
demonstrated that nucleosomes composed of acetylated histones assemble 
unmethylated DNA, whereby the addition of methyl groups on the identical DNA 
sequences correlates with the recruitment of non-acetylated histones (158). 
 Wnt signaling pathway plays a crucial role in normal colon epithelium 
development as well as in tumorigenic steps (5; 35).  During normal development, 
Wnt signaling is regulated and maintained at a normal level (33; 133).  Aberrant Wnt 
signaling has been proposed to promote colon carcinogenesis and is associated 
with over 90% of colorectal cancer cases (7; 37).  There is increasing evidence 
demonstrating that the epigenetic modifications of Wnt related genes correlate 
with the regulation of Wnt signaling during colon cancer development.  For 
instance, hypermethylation on the promoter regions of secreted frizzled receptor 
proteins (Sfrps) reduced gene expression of the Wnt antagonists and caused 
constitutive Wnt signaling during colorectal cancer progression (37).  Moreover, 
surveillance of Wnt signaling by Wnt inhibitors was diminished through altered 
histone modifications (45).   
In colon cancer cells, our group has previously shown that genistein 
increased the expression of Wnt signaling molecules, such as sFRP2 and 
WNT5a by demethylation of CpG within their promoters (39; 49).  We also reported 
that genistein induced the expression of DKK-1 by increasing histone H3 
acetylation at promoter region of the gene (44).  Only a few in vivo studies have 
been conducted to elucidate dietary genistein-induced epigenetic modifications 
and related changes in gene expression.  One study has shown gene-specific 
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changes in DNA methylation in mice fed a genistein-containing diet (92).  Another 
evidence that genistein affects DNA methylation was that maternal exposure to 
dietary genistein altered the epigenome of offspring in viable yellow agouti (Avy/a) 
mice.  Genistein induced hypermethylation of CpG in the viable yellow agouti 
(Avy/a) mice and decreased expression level of the Agouti gene (93).  No in vivo 
study has been reported regarding dietary genistein induced histone 
modifications in regulating gene expression.  
Dietary intake and epigenetic remodeling closely interact with each other 
and the balance of which is critical in maintaining normal development.  Thereby 
we conducted the current study to extend our knowledge of the epigenetic 
modifications by which dietary genistein maintained a normal expression profile 
of Wnt signals Sfrp2, Sfrp5, and Wnt5a in the AOM-induced colon neoplasia in 
rat (15).  In the previous study, we observed that the expression level of Sfrp2, 
Sfrp5 and Wnt5a, as well as the protein level of β-catenin, the hallmark of Wnt 
signaling activity, was maintained by dietary genistein in the post-AOM period.  
Importantly, the suppression of these Wnt signals was closely correlated with the 
decreased frequency of total aberrant crypt foci (ACF) in the colon.  These 
results indicated that rats fed a life-long GEN-containing diet were less affected 
by a carcinogen load, which probably occurred through maintaining a normal Wnt 
signaling by dietary GEN.  Here we demonstrated that dietary genistein 
maintained the expression of Sfrp2, Sfrp5 and Wnt5a at a low level in the colon 
epithelium of carcinogen-injected rats through regulating the DNA methylation 
and decreasing the acetylation of histone H3, methylation at histone H3K4 and 
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phosphorylation at histone H3S10 within the regulatory region of genes.  
Moreover, we have identified the potential crosstalk between DNA methylation 
and histone modifications at the CpG-rich region within the transcriptional 
regulatory region of Sfrp5.  
 
Materials and Methods  
Animal and Diets 
Detailed descriptions were included in our recent publication (Zhang et al, 
2013, Br. J. Nutr).  Briefly, timed-pregnant Sprague-Dawley rats (Charles River 
Laboratories) were purchased and fed one of three isocaloric diets throughout 
gestation and lactation periods.  The diets were AIN-93G diet formula-based: 1) 
CTL (casein protein), 2) SPI (soy protein isolate, NutroBio.com, contains 140 
mg/kg genistein aglycone equivalent), and 3) GEN (CTL plus 140 mg/kg 
genistein).  Diets were balanced and matched for content of protein, 
carbohydrate, fat, amino acids, vitamins, and minerals.  Using HPLC, the amount 
of genistein in SPI was measured to be 0.705± 0.025 mg/g.  So the genistein 
concentration in the SPI is 140 mg/kg diet and the GEN was formulated to match 
the amount of genistein in the SPI diet.  Male pups were weaned at d 24 and 
maintained on the same diet as their mother until sacrificed. Pre-AOM sampling 
of colon samples occurred when the offspring were 7-wk old (CTL, n=6, SPI and 
GEN, n=8). The rest of the rats were injected with AOM (15 mg/kg BW) at 7-wk 
and 8-wk of age. Post-AOM sampling of colon samples occurred 6 w later by 
CO2 asphyxiation. Colon tissues were collected for all subsequent analyses.  All 
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rats were kept individually in standard polycarbonate cages in a humidity- and 
temperature-controlled room, had free access to water and food.  All procedures 
were approved by the Institutional Animal Care and Use Committee at the 
University of Illinois at Urbana-Champaign.   
RNA isolation 
Scraped colon tissues were ground in liquid N2 and treated with TRI 
Reagent (Sigma-Aldrich).  Total RNA was isolated according to the 
manufacturer’s instructions.  RNA concentrations were measured by SmartSpec 
Plus Spectrophotometer (BioRad).  cDNA was synthesized from RNA using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA) in a Thermal Cycler 2720 (Applied Biosystems).  In each reaction system, 2 
µg of total RNA were used in a 20 µL mixture containing 1× RT buffer, 4 mmol/L 
dNTPs, 1× random primers, and 2.5 U/µL MultiScribe Reverse Transcriptase.  
cDNA synthesis was performed following the program: 25 °C for 10 min, 37 °C 
for 2 h, and 85 °C for 5 sec. 
Quantitative PCR analysis   
Synthesized cDNA for measuring gene expression, bisulfite converted- 
genome DNA for MSP assay, and antibody enriched-genome DNA for ChIP 
assay, were analyzed by PCR in a 7300 thermal cycler (Applied Biosystems).  In 
each reaction, 25 ng of synthesized cDNA, or 10 ng of genome DNA was used in 
a 20 µL volume containing 10 µL of SYBR Green master mix (2x, Applied 
Biosystems) and 0.25 µmol/L of each primer.  PCR was performed using the 
following program:  95 °C for 10 min, followed by 35 cycles of 95 °C for 15 sec 
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and 60 °C for 1 min.  After PCR, melting curves were acquired stepwise from 55 
to 95 °C to ensure that a single product was amplified in the reaction. The 
primers used in this study are listed in the Table 6.1 and 6.5 and in our previous 
publication (15).    
ChIP analysis  
ChIP analysis was performed following a modified protocol (167) that was 
routinely used in our laboratory. Briefly, 100 mg frozen descending colon 
epithelium samples from each individual were ground in liquid nitrogen and 
resuspended with ice-cold phosphate buffered saline.  Following the cross-linking 
in 1% formaldehyde, samples were lysed and chromatin was sonicated (Fisher 
Scientific F100 Sonic Dismembrator) on ice and the cell debris was removed 
after centrifugation. Sheared chromatin was diluted using ChIP Dilution Buffer.  
For each antibody of interest, 1 mL of the diluted lysate was incubated with 2 µg 
of antibody (Table 6.3) at 4 °C overnight, then the mixture was supplemented 
with the pre-blocked salmon sperm DNA/protein G agarose beads (60 µL, 50% 
slurry; Upstate Biotechnology).  After 2 h of incubation at 4 °C, all samples were 
centrifuged and the supernatant of normal rabbit IgG was reserved as input, 
while pellets containing the immunoprecipitated complexes were washed using a 
series of solutions.  Antibody/protein/DNA complexes were disassociated from 
Protein G beads in the elution buffer. Following flash spin, supernatants were 
combined and incubated at 65 °C for 5 h with 20 µL 5 mol/L NaCl and 1 µg of 
RNase A (Qiagen) to reverse the cross-linking and release the DNA fragments.  
Protein was removed by treating with proteinase K (Sigma) at 37 °C for 1 h, and 
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DNA was purified with a DNA miniprep system (Qiagen).  For each gene of 
interest, 5 uL of immunoprecipitated DNA was used for subsequent Quantitative 
real-time PCR reaction using specific primer set (Table 6.1). 
Methylation selective PCR (MSP) 
Genomic DNA was isolated from the colon tissues using DNeasy Tissue 
Kit (Qiagen). Bisulfite conversion was conducted as described previously (14). 
Three pairs of unmethylated (UM) primers (Table 6.2) were designed by 
MethPrimer (http://www.urogene.org/methprimer/index1.html) to analyze the two 
regions of interest (UM1 and UM2) and one region of control (UM3) for each 
gene. Ten ng of final product was used in each MSP reaction in a 20 µL volume 
containing 10 µL SYBR Green master mix (2x, Quanta) and 0.25 µmol/L of each 
primer followed by Quantitative RT-PCR. 
Bisulfite sequencing  
Bisulfite sequencing primers were designed for a putative 5′ upstream 
CpG island of Sfrp5 by MethPrimer 
(http://www.urogene.org/methprimer/index1.html), and listed in Table 6.2 (Sfrp5 
BSF).  Bisulfite conversion was conducted following the same methodology as 
described in the MSP section.  A total of 20 ng of the bisulfite-converted template 
was amplified by PCR.  Purified PCR products were cloned into pCR2.1-TOPO 
vector (Invitrogen).  Plasmid DNA was extracted using QIAprep Miniprep kit 
(Qiagen).  Individual clones were verified and sequenced at the Biotechnology 
Center at the University of Illinois at Urbana-Champaign (Urbana, IL). 
Protein isolation and immunoblotting   
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For isolating nuclear extracts, a total of 100 mg of scraped colon tissue 
was pulverized in liquid N2, washed and dislodged twice with ice-cold PBS, and 
collected by centrifugation at 500 × g.  Cell pellets were lysed with fresh lysis 
buffer (20 mmol/L HEPES pH 7.9, 10 mmol/L sodium chloride, 1.5 mmol/L 
magnesium chloride, 0.2 mmol/L EDTA, 20% glycerol (v/v), 1 mmol/L DTT 
(Roche), 1 mmol/L PMSF (Sigma), 1× protease inhibitor cocktail (Roche), and 
0.1% Igepal CA-630 (v/v) on ice for 15 min and centrifuged again.  Lysis was 
repeated for the resuspended pellet, followed by centrifugation at 500 × g. The 
precipitates were then incubated with fresh nuclear extraction buffer (20 mmol/L 
HEPES pH 7.9, 400 mmol/L sodium chloride, 1.5 mmol/L magnesium chloride, 
0.2 mmol/L EDTA, 25% glycerol (v/v), 1 mmol/L DTT, 1 mmol/L PMSF, 1× 
protease inhibitor cocktail) at 4 °C for 30 min.  Nuclear protein extracts were then 
collected from the supernatants after centrifugation at 12,000 × g.  Protein 
concentration was determined by Lowry assay.  For Western blot analysis, 30 mg 
of nuclear protein was size-fractionated on a 12% Tris–HCl polyacrylamide gel.  
Immunoblotting was performed by using a 1:1000 rabbit polyclonal antibody 
against HDAC3 (sc-11417, Santa Cruz Biotechnology), 1:1000 rabbit polyclonal 
antibody to detect Lamin A (Santa Cruz Biotechnology), and a 1: 10,000 goat-
anti-rabbit HRP-conjugated secondary antibody.  The membranes were exposed 
to the enhanced chemiluminescence reagent SuperSignal West Dura (Pierce), 
and the signals were detected and quantified using ChemiDoc XRS imaging 
system (Bio-Rad). 
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Statistical analysis   
 Results were reported as means ± SEM.  Differences were considered 
significant at P<0.05 unless otherwise mentioned.  Regression analysis was 
performed to examine the possible relationships between the intensity of 
unmethylation and the expression level of the gene.  Linear relationship was 
considered significant at P<0.05 (R program, http://www.r-project.org/).  Results 
from immunoblotting and real-time PCR were analyzed using two-way ANOVA 
(SAS Institute, Inc.) with interactions between dietary treatment and AOM-
induction as main effects.  One-way ANOVA was used to test the difference 
between treatment and control groups at the same time point.  Heatmaps were 
generated using R program.  The columns were scaled to have 0 as the mean 
and ± 1 as the standard deviation.   
 
Results 
DNA methylation status of a specific CpG –rich region was correlated with 
the gene expression of Sfrp2, Sfrp5, and Wnt5a  
Unmethylated CpGs at the regulatory region of a gene often represent an 
actively transcribing status of the gene (160).  We analyzed the relationship 
between the intensity of unmethylated CpG measured by MSP at two regions 
and the level of gene expression of Sfrp2, Sfrp5, and Wnt5a genes in the post-
AOM period using regression analysis.  We identified a specific region of each 
gene that displayed a significant correlation between level of unmethylated CpG 
and that of gene expression of the three genes (Figure 6.1, +102/+183 of Sfrp2, 
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p=0.013; -380/-295 of Sfrp5, p=0.056; +61/+128 of Wnt5a, p=0.031).  Alterations 
on DNA methylation at the above-identified regions were further analyzed to 
examine the effects of dietary genistein.  
 
Dietary genistein increased methylation of the specific CpG-rich region of Sfrp2, 
Sfrp5 and Wnt5a in the post-AOM period.   
To test whether dietary genistein suppressed the response of gene 
expression to a carcinogen load by affecting DNA methylation, the above-
identified CpG region of each gene was tested (Figure 6.2).  In the post-AOM 
period, decreased methylation was observed at +102/+183 of Sfrp2 in the GEN 
group (Figure 6.2A).  While AOM injection increased unmethylation at -380/-295 
of Sfrp5, SPI and GEN reduced the level of unmethylation at the same region by 
~33% (Figure 6.2B).  The +61/+128 region of Wnt5a did not show significant 
change of unmethylation (Figure 6.2C).  Using the intensity of methylation of 
Sfrp2, Sfrp5 and Wnt5a at the specified region as an indicator, we were able to 
discriminate the pattern of methylation of Sfrp2, Sfrp5 and Wnt5a in the SPI and 
GEN groups from the CTL group in the post-AOM period using heatmap analysis 
(Figure 6.2D).  Overall, SPI and GEN group displayed a trend of increased 
methylation in the post-AOM period within the indicated region of each gene, 
which was in agreement with the overall suppression of the gene expression by 
these two diets.   
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Dietary genistein suppressed binding of Pol II at the promoter of Sfrp2, 
Sfrp5 and Wnt5a in the post-AOM period  
To determine whether dietary genistein prevents AOM-induced gene 
expression by affecting transcriptional activity of the gene, we tested the binding 
of RNA Pol II at promoter regions of Sfrp2, Sfrp5, and Wnt5a (Figure 6.3, bars 
on primary y-axis).  Our results showed that AOM induced the binding of Pol II 
significantly.  SPI and GEN decreased the binding of Pol II at the promoter of 
Sfrp2, Sfrp5, and Wnt5a in the post-AOM period.  There was a strong interaction 
(P<0.01) between dietary treatment and AOM-induction for all three genes, 
meaning that dietary genistein affected the binding of Pol II differently in the pre- 
and post-AOM period. Without AOM induction, the Pol II binding at promoter 
region of these genes were the same among treatment groups. However after 
AOM induction, comparing to the upregulated binding of Pol II by AOM, SPI and 
GEN were able to maintain the Pol II binding to the similar level as that of the 
pre-AOM period.  Gene expression tested by RT-PCR analysis for each gene 
was also shown as the filled circles on the secondary y-axis (Figure 6.3).  The 
intensity of Pol lI binding was closely related to the level of gene expression 
(Figure 6.3).  This indicated that the reduction of gene expression by dietary 
genistein was caused by the decreased transcriptional activity.  
 
Dietary genistein reduced acetylation of histone H3 at the promoter of 
Sfrp2, Sfrp5 and Wnt5a in the post-AOM period  
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To investigate the overall histone landscape at the regulatory regions of 
genes, we examined the combinations of different types and sites of 
modifications on histone tails.  The ones that showed significant change by AOM 
induction and/or by diets were included in the discussion below.  We examined 
the effect of dietary genistein on histone acetylation by testing the level of histone 
acetylation (H3Ac and H4Ac) at the promoter regions of Sfrp2, Sfrp5 and Wnt5a.  
Although dietary genistein did not alter the level of H4Ac in either pre- or post-
AOM period (data not shown), H3Ac level at the promoters of Sfrp2, Sfrp5, and 
Wnt5a were downregulated to about 50% by SPI and GEN diets in the post-AOM 
period (Figure 6.4, left panel).  There is a strong interaction between dietary 
treatment and AOM-induction for H3Ac on Sfrp5 and Wnt5a (P<0.01), indicating 
that the diet affected acetylation at histone H3 differently in the pre- and post-
AOM period.  Therefore dietary genistein affected the expression of Wnt genes 
by decreasing the acetylation of lysine residues at histone H3 at the specific 
regions of the genes.   
 
Dietary genistein repressed methylation of Lysine 9 and phosphorylation of 
Serine 10 of histone H3 at the promoter of Sfrp2, Sfrp5 and Wnt5a in the 
post-AOM period 
We tested the effect of dietary genistein on methylation (trimethyl lysine 9, 
H3K9Me3) and phosphorylation (serine 10, H3S10P) of histone H3.  The two 
neighboring histone modifications have been shown to interact with each other, 
leading to activation or inactivation of gene expression (161).  In the pre-AOM 
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period, there was no difference among the dietary groups in terms of these 
modifications of histone H3 on the genes examined, indicating minimal influence 
from the diets under normal conditions (Figure 6.4, middle and right panels).  
After AOM injection, the level of H3K9Me3 and H3S10P at promoter of Sfrp2 and 
Sfrp5 was significantly increased in CTL group compared to the CTL in pre-AOM.  
Increased intensity of these histone modifications at the promoter region of the 
genes parallel the increased gene expression observed in the post-AOM control.  
In the post-AOM period, H3K9Me3 and H3S10P were both decreased by SPI 
and GEN when compared to CTL.  GEN but not SPI reduced the level of 
H3K9Me3 and H3S10P at promoter of Wnt5a.  Statistical analysis showed a 
strong interaction (P<0.01) between dietary treatment and AOM-induction at all 
three genes.  
 
Dietary genistein induced the nuclear level of HDAC3 protein in the post-
AOM period  
To identify the potential regulators of histone acetylation, nuclear level of 
HDAC3 protein was examined.  The level of HDAC3 was increased by about 3 
folds in SPI and GEN in the post-AOM period (Figure 6.5).  There was a strong 
interaction (P=0.016) between dietary treatment and AOM induction, suggesting 
that the effect of dietary treatment on HDAC3 was different between pre- and 
post-AOM period.  This indicates that SPI and GEN diets suppressed the 
acetylation of histone H3 by upregulating HDAC3 in the nuclei of colon epithelial 
cells.   
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Dietary genistein induced an increase of CpG methylation and a decrease 
of histone H3 acetylation at the same region of Sfrp5 promoter after AOM 
induction 
We further examined dietary genistein-induced methylation at individual 
CpG site within the CpG-rich region at Sfrp5 promoter (-314/+137, Figure 6.6) 
using bisulfite sequencing.  The region mapped by bisulfite sequencing was 
overlapped with the one (-380/-295) that had a decreased level of unmethylation 
in the post-AOM SPI and GEN group detected by MSP assay (Figure 6.2B).  
Comparing with an average of 12.5% methylation out of total 20 CpGs within the 
bisulfite sequencing-covered region in CTL group, GEN had an average 
methylation of 16.5%.  This confirmed the increase of DNA methylation by 
genistein diet by MSP analysis.  Importantly, further analysis showed that the 
CpG methylation of -162/-74 within the sequenced region had an average of 
27.5% in the GEN group, which was 90% higher compared to CTL (15%, 
P=0.05).  Notably, the -162/-74 region also had a 3-fold decrease of H3Ac by 
GEN (Figure 6.4, box-highlighted in Figure 6.6).  
 
Discussion 
The current study provides the first evidence that epigenetic remodeling is 
critical for the repression of Wnt signaling by genistein during colon cancer 
development.  We report that DNA methylation of the proximal regions on 
selected genes of the Wnt pathway is closely related to the decreased gene 
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expression.  Alterations of histone configurations at these critical regions were 
also associated with the regulation of gene expression by dietary genistein.  
Importantly, investigations on the CpG-rich promoter region of the Sfrp5 gene 
revealed a strong association between increased DNA methylation and 
decreased acetylation, methylation, and phosphorylation of the histone H3.  
Overall, this study provides the identification of critical epigenetic markers on the 
regulation of gene expression during colon cancer development.  
Many lines of evidence have shown that genistein treatment modulates 
gene expression through mediating chromatin configurations or DNA methylation 
of gene in cancer cells.  We have previously presented that dietary genistein 
maintained the WNT/β-catenin signaling at a low level, therefore suppressed the 
formation of ACF in the descending colon of rats during carcinogen induction (15).  
In that publication, it is shown that the β-catenin signaling was greatly induced 
after the carcinogen load.  But SPI and GEN diet kept β-catenin expression at the 
pre-induction level, indicating that the protection from dietary genistein against 
ACF formation was mediated through the maintenance of the proper β-catenin 
signaling (15).  As the nuclear β-catenin increased in the control group after AOM 
injection, the expression of Sfrp2, Sfrp5, and Wnt5a was significantly induced.  
On the contrary, SPI and GEN maintained the expression of these three genes 
and the nuclear β-catenin at the same level as that of pre-AOM period, 
suggesting a promising role of dietary genistein in maintaining colon health by 
preventing the over-activation of WNT/β-catenin signaling induced by a 
carcinogen load.  In the current study, we focused on elucidating the mechanism 
	   86	  
of how dietary genistein mediated and kept the expression level of Sfrp2, Sfrp5, 
and Wnt5a low in the descending colon after AOM injection by examining the 
alterations of epigenetic structures of these genes.  In this report, it is shown that 
the changing patterns of Pol II association at the promoter region of Sfrp2, Sfrp5, 
and Wnt5a were in accordance with that of the gene expression, indicating that 
the regulation of gene expression of Sfrp2, Sfrp5, and Wnt5a by genistein 
occurred at the transcriptional level.   
It has been reported that genistein increases acetylation of histone tails 
and upregulates the expression of tumor suppressor genes in prostate cancer 
cells (80; 162).  Our results showed that the decreased level of histone H3 
acetylation at promoters of Sfrp2, Sfrp5, and Wnt5a in the post-AOM period 
paralleled with the down-regulation of the gene expression.  As one of the major 
nuclear histone deacetylases, HDAC3 has been shown to be more susceptible 
than other HDACs to dietary factors such as sulforaphane in colon cancer cells 
(163).  We therefore tested the effect of dietary genistein on the nuclear HDAC3 
protein abundance.  Our result showed that in accordance with the decreased 
histone H3 acetylation, dietary genistein upregulated the nuclear level of HDAC3, 
which played a critical role in the transcriptional regulation, in the post-AOM 
period.  Our observations suggested that the increase of nuclear HDAC3 by 
dietary genistein caused a reduction of acetylation of histone H3, leading to a 
decreased gene expression.   
In addition to modulating histone acetylation, genistein has also been 
shown to reduce the methylation of H3K9 and restore the gene expression in 
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prostate cancer cells (81).  In the present study, we observed the similar 
downregulation of the methylation of H3K9 by genistein at the promoter of the 
selected genes in rat colon in the post-AOM period.  The fact that dietary 
genistein decreased the gene expression of Sfrp2, Sfrp5, and Wnt5a at the same 
time of the downregulation of the H3K9Me3 clearly demonstrated the complex 
interactions among the histone tail residues in the cancer development model in 
vivo.  
Phosphorylation of histone H3S10 has been used as a marker for mitotic 
fraction of cell cycle progression in cancer (164).  Decrease of the phosphorylation 
at H3S10 was observed in breast cancer cells after genistein treatment, and it 
contributed to the reduced cell cycle progression into mitosis.  In the present 
study, we observed more than two folds of increase in phosphorylated H3S10 by 
AOM induction, demonstrating the tumorigenic potential of this carcinogen.  Our 
result also showed that the binding of H3S10P at promoter region of Sfrp2, Sfrp5 
and Wnt5a was reduced by dietary genistein in the post-AOM period, suggesting 
a possible role of the phosphorylated H3S10 in modulating gene expression at 
the regulatory region of gene.  Although it has been reported that the 
phosphorylation of H3S10 suppressed the methylation of neighboring H3K9 (165), 
we observed a simultaneous reduction of both modifications by dietary genistein 
at the promoters of transcriptionally repressed genes.  Overall our results on the 
interactions of selected histone tail modifications by diet during carcinogenesis 
illustrated the critical involvement of all histone modifications as well as the 
complex interactions among them.  Further studies are needed to decipher the 
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interactions among these epigenetic markers, which will lead to a better 
understanding of the regulation of oncogenes at epigenetic level.   
  Change of DNA methylation at the regulatory region of gene with rich CpG 
content has profound influence on gene expression (83).  It is well known that 
during cancer development, hypomethylation leads to oncogene activation (166).  
In the present study, we have shown that the increased methylation at the 
promoter region of Sfrp2, Sfrp5, and Wnt5a was correlated with the reduced 
expression of these genes, suggesting that the genistein-induced methylation 
might be responsible for the change of gene expression.  Importantly, the 
heatmap generated from our data analysis indicates a potential use of the 
methylation panel of Sfrp2, Sfrp5 and Wnt5a as a molecular marker to 
discriminate and identify colon cancer development.   
As the two major epigenome regulators, DNA methylation and histone 
modifications do not only work independently, but also crosstalk with each other, 
leading to the proper configuration of transcriptional machinery, which is crucial 
for regulating gene expression (162).  Besides confirming the results that genistein 
increased the methylation of CpG at the promoter region of Sfrp5 by MSP assay, 
bisulfite sequencing provided the first clue of the potential association between 
DNA methylation and histone modifications on transcriptional regulation of gene 
mediated by dietary genistein.  Importantly, higher methylation at the region 
which had decreased level of H3Ac, H3K9Me3 and H3S10P by dietary genistein 
was observed in GEN group, suggesting a combined effect of increased DNA 
methylation and histone modifications on the regulation of Sfrp5 expression by 
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dietary genistein.  Future studies are needed to provide mechanistic explanations 
to genistein-mediated interaction between DNA methylation and histone 
modifications. 
In summary, we presented the first evidence that dietary genistein 
maintains a normal Wnt signaling in the colon epithelium of carcinogen-injected 
rats through regulating the epigenetic structures of Wnt genes.  The results 
elucidated that dietary genistein supervised the expression of Wnt genes through 
altering the methylation content and histone codes at the regulatory region of the 
genes, suggesting a promising role of dietary genistein in preventing colon 



























Figure 6.1 Correlation between DNA methylation and gene expression of 
Sfrp2, Sfrp5, and Wnt5a of rat descending colons in the pre- and post-AOM 
period.  Regression analysis was performed to illustrate the correlation between 
the level of unmethylation and that of expression of Sfrp2 (A), Sfrp5 (B) and 
Wnt5a (C).  Samples were collected from control (CTL, npre-AOM=6; npost-AOM=8), 
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Figure 6.2 Change of DNA methylation of Sfrp2, Sfrp5 and Wnt5a in rat 
descending colons.  Intensity of unmethylation at promoter of each gene was 
presented (A: Sfrp2, B: Sfrp5 and C: Wnt5a).  Samples were collected from 
control (CTL, npre-AOM=6; npost-AOM=8), soy protein isolate (SPI, npre-AOM=8; npost-
AOM=8), and genistein (GEN, npre-AOM=8; npost-AOM=8) diets.  Data were shown as 
ratio of unmethylation intensity of the region of interest to that of the region of 
control, and presented as means ± SEM.  *, significant difference compared to 
CTL in post-AOM, P<0.05.  (D) Heatmap of the intensity of unmethylation at 
+102/+183 of Sfrp2, -380/-295 of Sfrp5, and +61/+128 of Wnt5a.  Samples from 
four rats in each group were analyzed and presented.  Each square represents 
the methylation level of the gene from an individual rat.  The data are scaled to 0 
as the mean and ±1 as the standard deviation. Color intensity indicates level of 
methylation.  
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Figure 6.3 Binding of RNA polymerase II (Pol II) at the promoter of Sfrp2, 
Sfrp5 and Wnt5a of rat descending colons in the pre- and post-AOM period.  
Samples from four rats in each group were analyzed and presented as the 
means ± SEM.  Bars (□, ■) were shown as mean ratios of the binding of Pol II to 
that of IgG and scaled on the primary Y axis (left).  Dots (●) represent means ± 
SEM of gene expression and scaled on the secondary Y axis (right).  *, mean 
values that are significantly different compared to CTL counterpart within the 
same time period, P<0.05.  ≠, mean values of CTL that are significantly different 
compared to the CTL in pre-AOM, P<0.05.   
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Figure 6.4 Histone acetylation, methylation and phosphorylation at the 
promoter of Sfrp2, Sfrp5 and Wnt5a in rat descending colon.  Left panel, 
acetylated histone H3 (H3Ac); Middle panel, trimethylated histone H3K9 
(H3K9Me3); Right panel, phosphorylated histone H3S10 (H3S10P).  ChIP was 
performed using antibodies against the specific histone tail modifications and the 
raw values were normalized to the negative control IgG.  Samples from four rats 
in each group were analyzed and data were presented as the means ± SEM.  *, 
mean values that are significantly different compared to CTL counterpart within 
the same time period, P<0.05.  ≠, mean values of CTL that are significantly 
different compared to the CTL in pre-AOM, P<0.05.   
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Figure 6.5 Nuclear HDAC3 abundance in rat descending colon.  (A) 
Representative blots of HDAC3 and Lamin A from western blot analysis.  (B) 
Quantification of western blot analysis.  Lamin A served as the loading control for 
nuclear extracts.  Samples from three rats in each group were analyzed and data 
were presented as the means ± SEM.  *, mean values that are significantly 
different compared to CTL counterpart within the same time period, P<0.05. 
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Figure 6.6 DNA methylation at Sfrp5 promoter in rat descending colon after 
AOM induction.  Bisulfite sequencing was performed to detect the change of 
DNA methylation at the proposed CpG island of Sfrp5 (-314/+137).  Each CpG 
site is underlined in the tested region (Top panel).  Ten clones from each dietary 
group were sequenced and presented (bottom panel).  Open circles represent 
unmethylated CpG sites while filled circles represent methylated CpG sites.  
Each row of circles represents an individual clone used for sequencing.  Framed 
circles indicate the overlapping region (-162/-74) with ChIP assay.    
  
	   96	  
Tables 
Table 6.1 Primer sets for ChIP analysis. 
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Table 6.2 Primer sets for MSP analysis and bisulfite sequencing. 
  




Sfrp2 UM2  
(-1896/-1830) 
5ʹ′-TGGGTTTTTTAAATAATGTTTAGGTTT-3ʹ′ 5ʹ′-AAAAAACAACAAACTACCCATACAC-3ʹ′ 
Sfrp2 UM3  
(+7696/+7834) 
5ʹ′-TGGTTTATTTTTTAGGTTGTATGG-3ʹ′ 5ʹ′-CACCCCCTACTTCTTCTAATCATA-3ʹ′ 
Sfrp5 UM1  
(-380/-295) 
5ʹ′-GGTAGAATTTTGGGGTATTTTTGA-3ʹ′ 5ʹ′-CTAAAATCTCTTAACCATCCACACC-3ʹ′ 
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Antibody Catalog Number Source 
Name  Modification    
IgG  sc-2027 Santa Cruz Biotechnology, CA 
Pol II CTD4H8  05-623 Millipore, CA 
H3Ac Ac-K9, 14 06-599 Millipore, CA 
H3K9Me3 M-K9 07-422 Millipore, CA 
H3S10P P-S10 Sc-8656-R Millipore, CA 
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Chapter 7: Future Direction 
During the previous 5 years, I have been exploring the protective effect of 
soy isoflavone genistein against colon cancer development. Our studies have 
provided exciting and novel evidence of genistein acting as a promising anti-
colon cancer food agent. Our observations indicate that the lifelong consumption 
of soy genistein reduced the formation of pre-neoplastic lesions in colon of 
carcinogen-injected rats. Dietary genistein repressed the development of colon 
epithelial abnormality at least in part by maintaining a normal level of Wnt 
signaling when the rats were exposed to a carcinogen. By comparing two time 
points, the pre- and post-carcinogen period, we concluded that dietary genistein 
did not affect Wnt signaling during normal colon development, but repressed its 
over-activation induced by the carcinogen.  Importantly, our results provided the 
first clue that dietary genistein prevent the over-activation of Wnt signaling genes 
by altering their epigenetic structures.   
However, genistein is double-edged sword, and thereby should not be 
considered a magic pill for cancer treatment. As summarized in the literature 
review section, the outcomes from genistein-related studies have been 
controversial. Due to its estrogenic effect, genistein could promote the 
proliferation of cancer cells rather than diminish it. Colon abnormality was 
reported in a study where the rats were fed a genistein-containing diet after being 
injected with a carcinogen (129). The adverse effect was also observed in some 
studies using a very high dose of dietary genistein. The positive and negative 
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characteristics of genistein raised the question of what are the deciding factors of 
its properties? The answer appears to be timing and dosage.  
In order to receive the protection from dietary genistein, it is critical to 
choose the appropriate starting point for exposure and the amount of 
consumption. Previously, scientists believed that Asians have a much lower risk 
of developing colon cancer than Americans because they consume more soy 
products, thereby exposing themselves to a higher level of genistein. The 
misunderstanding of this epidemiological study led to the irrationally high intake 
of genistein supplements in the US. However, we now know that to better 
comprehend the cancer protection that Asians gain from consuming dietary 
genistein, it is necessary to understand the way in which they are expose to 
dietary genistein. Asians begin consuming genistein-containing soy diet when 
they are young and healthy, and most are also exposed to the diet from maternal 
nutrition during the fetal period and as infants though breast milk. Moreover, 
Asian people consume a genistein-containing soy diet on a daily basis in the 
form of tofu, miso soup, soymilk and edamame, where the genistein 
concentration is at physiologically relevant levels, and not as high as that in 
genistein supplements. Therefore, the consensus has become that dietary soya 
genistein may be of most benefit when consumed as early as possible in life, and 
in the form of whole food. Furthermore, genistein is not recommended for patient 
with already established tumors. 
Future studies have to be conducted to elucidate the controversial roles of 
genistein in caner development. By understanding the epigenetic mechanism by 
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which genistein protects again cancer initiation and by which it accelerates 
cancer progression, the scientific community could begin to help clinicians make 
recommendation about the timing and dosage of dietary genistein.  
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Appendix A : Gender Differences In Response To Dietary Genistein During 
Colon Cancer Development 
Aims: Based on the observations and experience gained from our 
previous animal studies, we further: 1) compared the effect of genistein on the 
the development of colon pre-neoplastic lesions in female rats to that of male rats; 
2) compared the response of Wnt signaling gene expression to dietary genistein 
in the colon of female rats to that of male rats; 3) compared the chromatin 
modifications on Wnt genes induced by dietary genistein in the colon of female 
rats to that of male rats; 4) investigated the response of ERβ to dietary genistein 
in the pre-neoplastic female and male rat colons. 
Animal model: Male and female rats exposed to the same diets used in 
our previously published study (15) were mated for five days.  Pregnant dams 
were then fed with their same diet throughout gestation and lactation. Pups were 
weaned at three weeks of age, and fed the same diet as their mothers. At ten 
weeks of age, rats were given an Azoxymethane (AOM) injection of 15 mg/kg of 
body weight. Food intake and body weight were recorded for an additional five 
weeks.  At week fifteen, animals were killed using CO2 asphyxiation and tissue 
samples were collected for future analysis.  Tissue collection and all subsequent 
analysis followed the method we used in the previous study (15). 
Results: We first quantified the total number of ACF in the descending 
colon of female and male rats (Figure A.1). Our result indicated that SPI reduced 
the total ACF significantly in both male and female rats. GEN repressed the total 
ACF formation in female colon but not in male colon. We further subgrouped 
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ACF according to the number of openings (Figure A.2). We observed that the 
number of n=1 ACF was not repressed by SPI or GEN in either male or female 
colons. SPI decreased the formation of n=2 ACF in male colons and n≥3 ACF in 
female colons. GEN repressed the development of n≥3 ACF in male colons. 
Although there was no statistic significance, female rats fed GEN in general had 
fewer n=1, n=2 and n≥3 ACF compared to CTL, which could explain the 
significant repression on the total ACF by GEN. To visualize the similarity of 
developing ACF between different samples, we generated the dendrogram and 
ACF heatmap according to the number of total, n=1, n=2, n=3 and n=4 ACF 
(Figure A.3). On the dendrogram, we observed that the male rats were split into 
3 major groups according to the hierarchical structure, indicating that there were 
3 different patterns of ACF development. Female rats were split into 2 major 
groups, suggesting 2 different pattern of ACF development. However, the major 
separations we observed were not clearly correlated to the different dietary 
treatments.  
We next compared the difference in the response of Wnt and ER genes to 
dietary genistein between male and female rats. We previously concluded that 
Wnt signaling was greatly induced by the carcinogen induction, and dietary 
genistein modulated the expression of Wnt genes during colon cancer 
development. In the current study, we included other Wnt genes in our analysis 
in addition to the ones we tested previously. Additionally, in order to study the ER 
response to dietary genistein, we tested the expression of ERα and ERβ in both 
male and male colons. Using a heatmap to analyze the expression of a panel of 
	   114	  
genes, we observed that in females, the GEN group had distinct pattern of gene 
expression when compared to CTL or SPI (Figure A.4). We did not observe a 
clearly different gene expression pattern between groups in male rats. When 
considering the genes we tested as a panel, our results indicate that the pre-
neoplastic male and female rat colons responded differently to dietary genistein. 
Furthermore, we tested histone modifications and the binding of ERα and 
ERβ at the promoter of Wnt1, Wnt5a, Wnt6, Wnt8b, Wnt16, Sfrp2 and Sfrp5 in 
both male and female rat colons (Figure A.5, A6). In general, our results indicate 
that GEN repressed the phosphorylation of H3S10 at the promoter of tested 
genes in the pre-neoplastic male and female colons. SPI decreased the 
phosphorylation of H3S10 compared to CTL in male but not in female rats. 
Interestingly, male CTL colons had overall higher intensity of pH3S10 at the 
promoter of tested genes than females, which could potentually explain the 
reason why we observed a less repressive effect of SPI and GEN on pH3S10 in 
female colons. GEN induced the binding of ERβ but not ERα at the promoter of 
tested genes compared to CTL in both male and female colons. Except the 
difference in pH3S10 intensity between male CTL and female CTL, we did not 
observe any other obvious gender differences in chromatin structure at the 
promoter of tested genes. 
To investigate the response of ERβ expression to dietary genistein in male 
and female rats, we tested the mRNA (Figure A.7), and protein level of ERβ 
(Figure A.8). Our result showed no significant dietary effect on the mRNA level 
in male colons. In the female colons, SPI decreased but GEN increased the level 
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of ERβ mRNA significantly compared to CTL. Interestingly, despite the fact that 
the binding of ERβ at the promoter of tested genes was upregulated by GEN, the 
protein expression data showed that there was no significant dietary effect on the 
ERβ protein content in the whole cell lysis of either male or female colon 
epithelium. Our results indicate that the upregulation of ERβ by GEN was 
potentially gene promoter region specific.  
Moreover, we tested the protein level of pH3S10 in the whole cell lysis of 
colon epithelium (Figure A.8). We did not observe similar dietary effect on the 
pH3S10 as we observed at the promoter of tested genes. However, the level of 
pH3S10 was overall lower in female, which paralleled our observation at the 
promoter regions that the female pre-neoplastic colons had lower pH3S10 
compared to the males.   
  




Figure A.1: Distribution of total aberrant crypts per colon section. Dot indicates 
the number of total aberrant crypts of individual rat. * Different from CTL, P< 0.05. 
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Figure A.2: Distribution of aberrant crypts with different number of opening per 
colon section. Dot indicates the number of total aberrant crypts of individual rat. n 
indicates the number of opening of the aberrant crypt foci. * Different from CTL, 
P< 0.05.
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Figure A.3: Similarity of the development of ACF in different diet groups. 
Intensigy of color increases as the number of ACF increases. 
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Figure A.4: Heatmap of gene expression in the colon of rats fed different diet. 
Color changes from red to green as the expression level changes from low to 
high. Blue lines indicate the separation of dietary groups. 
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Figure A.5: Histone modifications and the binding of ERα and ERβ at the 
promoter of Wnt1, Wnt5a, Wnt6, and Wnt8b in both male and female rat colons. * 
Different from CTL, P< 0.05. 
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Figure A.6: Histone modifications and the binding of ERα and ERβ at the 
promoter of Wnt16, Sfrp2 and Sfrp5 in both male and female rat colons. * 
Different from CTL, P< 0.05. 
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Figure A.7: Response of the mRNA expression of ERβ to dietary genistein in 
male and female rat colon epithelium. * Different from CTL, P< 0.05. 
  
















Figure A.8: Response of the protein expression of ERβ to dietary genistein in 
male and female rat colon epithelium.  
 
